Pigeon Circovirus

Overview and Taxonomy of Pigeon Circovirus

Taxonomic Classification and Virion Structure

Pigeon circovirus (PiCV) is a highly prevalent, economically significant pathogen of domestic and feral pigeons (Columba livia domestica) that occupies a well-defined position within the virosphere. Taxonomically, PiCV is classified within the genus Circovirus, family Circoviridae, order Cirlivirales, phylum Cressdnaviricota [8, 27]. The family Circoviridae encompasses some of the smallest known autonomously replicating viruses, characterized by a circular, single-stranded DNA (ssDNA) genome of approximately 2.0–2.1 kilobases [3, 5, 27]. This genomic architecture places PiCV among a growing assemblage of economically and ecologically important circoviruses, including porcine circovirus type 2 (PCV2), beak and feather disease virus (BFDV) in psittacines, goose circovirus (GoCV), duck circovirus (DuCV), and canine circovirus (CanCV) [4, 31]. The virion itself is non-enveloped, icosahedral, and remarkably small, with a diameter typically ranging from 12 to 26 nm as determined by electron microscopic examination of virus-like particles (VLPs) assembled from recombinant capsid protein [13, 19]. This diminutive size belies the profound pathological consequences of infection, particularly the induction of profound immunosuppression that predisposes birds to a spectrum of secondary and opportunistic infections [6, 14, 16, 27].

The PiCV genome encodes two major open reading frames (ORFs) oriented in opposite directions, a hallmark ambisense organization characteristic of circoviruses. ORF V1 (or rep) encodes the replication-associated protein (Rep), a multifunctional enzyme essential for rolling-circle replication of the viral genome, while ORF C1 (or cap) encodes the sole structural protein, the capsid (Cap) protein, which is responsible for virion assembly, host cell receptor recognition, and immunogenicity [2, 3, 23, 27]. The Cap protein is the primary target of the host humoral immune response and contains critical neutralizing antibody epitopes, making it the focus of diagnostic assay development and vaccine candidate design [1, 13, 18, 20, 23]. Between the 5′ ends of these two major ORFs lies a stem-loop structure within the intergenic region that serves as the origin of replication, a conserved feature essential for viral genome replication [27].

Historical Context and Initial Discovery

The first definitive descriptions of PiCV emerged in the early 1990s, when histopathological examinations of bursal tissue from diseased squabs revealed characteristic basophilic, botryoid intracytoplasmic inclusion bodies within lymphocytes and macrophages, accompanied by severe lymphoid depletion and atrophy of the bursa of Fabricius [8, 27]. These lesions were strikingly similar to those observed in chickens infected with chicken anemia virus and in psittacines infected with BFDV, prompting investigations into a circoviral etiology. Subsequent molecular characterization using nested PCR and sequencing confirmed the presence of a novel circovirus in pigeons, and the virus was formally designated pigeon circovirus [24, 27]. Since its initial identification, PiCV has been documented on nearly every continent where pigeon populations exist, including Europe, Asia, Australia, North America, Africa, and the Middle East, underscoring its global distribution and ecological success [2-4, 7, 26, 27, 29].

Genetic Diversity and Phylogenetic Architecture

One of the most striking features of PiCV is its extraordinary genetic diversity, which far exceeds that observed in many other circoviruses. Whole-genome sequencing and phylogenetic analyses of PiCV strains collected from diverse geographic regions and host populations have revealed the existence of at least 12 to 13 distinct genotypes or clades, with some studies proposing up to 18 or more genogroups depending on the genetic markers and demarcation criteria employed [2, 5, 12, 27]. This genetic heterogeneity is most pronounced in the cap gene, where nucleotide sequence identities among strains can be as low as 64.5–71.9%, while amino acid identities of the Cap protein range from 64.5% to 100% [3, 7, 17, 21]. In contrast, the rep gene is relatively more conserved, though it too exhibits substantial variation, with unique amino acid substitutions frequently observed in field strains [7, 17, 21].

Phylogenetic analyses based on complete genome sequences or the cap gene have consistently resolved PiCV strains into multiple well-supported clades, often designated A through I or more recently as GI, GII, and other groupings, depending on the study and the reference sequences included [3, 7, 11, 17, 21]. For instance, a comprehensive study of PiCV in racing pigeons from 11 provinces in China identified seven distinct clades (A, B, C, E, G, H, and I), with strains distributed across these groups exhibiting high genetic diversity and frequent recombination [7, 17, 21]. Similarly, investigations of PiCV in Australian feral pigeons and other Columbiformes have revealed two strongly supported monophyletic clades, one of which clustered with global strains from Poland, the United Kingdom, Belgium, China, and Japan, while a second, more basal clade showed closer affinity to Polish isolates [29]. This global phylogeographic structure suggests that PiCV has undergone extensive radiation and dispersal, likely facilitated by international trade in racing and fancy pigeons, as well as by the movements of feral populations [2, 26, 27].

Recombination as a Driver of Genetic Diversity

Recombination is a major evolutionary force shaping PiCV genetic diversity and has been documented at exceptionally high frequencies across multiple studies [2, 3, 5, 7, 11, 12, 27, 29]. Recombination events have been detected in PiCV genomes from diverse geographic regions, including China, Australia, Poland, and the United States, and they frequently involve exchanges between strains belonging to different clades [3, 5, 12, 29]. For example, in a study of PiCV in racing pigeons from Heilongjiang Province, China, the complete genome of strain HLJ2024 was shown to have arisen from recombination between a major parent strain (GF17/GuangDong/2014) and a minor parent strain (TY2/SN/2016), both of Chinese origin [11]. Similarly, a large-scale investigation of PiCV in racing pigeons from 11 Chinese provinces identified 31 recombination events among the genomes analyzed, with breakpoints distributed across the rep gene, the intergenic region, and the cap gene [7, 17, 21].

The frequency and distribution of recombination breakpoints are non-random, with certain genomic regions serving as recombination hotspots while others are relatively cold. A detailed recombination analysis of 178 PiCV genome sequences obtained from pigeons housed in a single loft revealed a recombination hotspot spanning the 3′ region of the genome, the rep gene, and the intergenic region, while a cold spot was identified in the capsid protein-coding region [12]. This pattern suggests that purifying selection may act to preserve the structural integrity of the Cap protein, which is essential for virion assembly and host cell recognition, while the rep gene may tolerate greater genetic exchange [12, 27]. The high recombination rate in PiCV has important implications for viral evolution, as it can generate novel genotypes with altered antigenic properties, tissue tropism, or pathogenic potential, potentially complicating diagnostic detection and vaccine development [2, 5, 27].

Host Range and Spillover Infections

While PiCV is primarily recognized as a pathogen of domestic and feral pigeons (Columba livia), accumulating evidence indicates that its host range extends beyond the Columbidae family. PiCV DNA has been detected in Eurasian collared-doves (Streptopelia decaocto), suggesting that the virus can infect other columbiform species [25]. More strikingly, PiCV has been identified in non-columbiform hosts, including a common raven (Corvus corax) presenting with bursal lymphoid depletion and inclusion bodies characteristic of circovirus infection [15]. In Australia, PiCV Rep sequences were recovered from clinically affected plumed whistling ducks (Dendrocygna eytoni), blue-billed ducks (Oxyura australis), and an Australian magpie (Gymnorhina tibicen), providing compelling evidence for natural spillover infection and demonstrating that PiCV exhibits host generalist characteristics [26]. These findings challenge the traditional view of PiCV as a strictly pigeon-adapted virus and raise important questions about its ecological dynamics, transmission pathways, and potential for cross-species transmission in mixed-species aviaries, zoological collections, and wild bird populations [26, 29].

Molecular Epidemiology and Global Distribution

The global prevalence of PiCV is remarkably high, with infection rates often exceeding 50–90% in surveyed pigeon populations, regardless of geographic location or clinical status [2-4, 7, 22, 27]. In China, a large-scale molecular epidemiological study of racing pigeons conducted between 2016 and 2019 reported a sample-level positive rate of 19.3% (120/622) and a club-level positive rate of 59.0% (23/39), indicating widespread circulation within racing pigeon populations [7, 17, 21]. Even higher prevalence rates have been documented in other settings: a study of PiCV in Beijing found that all 40 pigeons tested from a single farm were positive for PiCV DNA in at least three tissue types, with 29 complete genomes recovered [3]. In Iran, PiCV was detected in 86% (86/100) of fecal samples collected from pigeons with clinical signs suggestive of YPDS [4]. In Australia, PiCV prevalence in feral rock doves was reported at 76% [29], while in Poland, approximately 70% of asymptomatic domestic pigeons tested seropositive for anti-PiCV antibodies [22]. These data collectively indicate that PiCV is endemic in pigeon populations worldwide and that subclinical infections are exceedingly common [8, 22, 27].

The detection of PiCV in ticks (Hyalomma asiaticum and Dermacentor nuttalli) collected from sheep and camels in Inner Mongolia, China, raises the intriguing possibility of arthropod-borne transmission, though the epidemiological significance of this finding remains to be determined [28]. Additionally, PiCV DNA has been identified in environmental samples from high-risk port-of-entry environments, including customs facilities in Belgium, suggesting that the virus can be transported across international borders via contaminated fomites or infected birds [30]. These findings underscore the need for enhanced biosecurity measures and surveillance at ports of entry to mitigate the risk of introducing novel PiCV strains into naive populations [30].

Implications for Disease Control and Future Research

The extraordinary genetic diversity and high recombination rate of PiCV pose significant challenges for the development of broadly protective vaccines and universally applicable diagnostic assays. The capsid protein, while immunogenic, exhibits substantial sequence variation, particularly within the N-terminal region spanning amino acids 30–120, which is a major target of the host antibody response [2]. However, a relatively conserved region spanning amino acids 140–180 of the Cap protein has been identified as possessing strong antigenicity, suggesting that it may serve as a promising target for subunit vaccine development [2]. Indeed, recombinant Cap protein expressed in E. coli, baculovirus, or mammalian cell systems can self-assemble into VLPs that are morphologically and immunologically similar to native virions, and these VLPs have been shown to induce robust humoral and cell-mediated immune responses in pigeons [13, 19, 20, 23]. Despite these advances, no inactivated or live-attenuated PiCV vaccine is currently commercially available, primarily due to the inability to propagate PiCV in conventional cell culture systems [1, 13, 19, 27].

The World Organisation for Animal Health (WOAH) recognizes circovirus infections as significant emerging diseases in avian species, and the Food and Agriculture Organization (FAO) of the United Nations has highlighted the importance of surveillance and control of immunosuppressive viral diseases in poultry and pigeon populations to safeguard food security and rural livelihoods. The development of pan-genotypic serological assays, such as the indirect competitive ELISA (icELISA) targeting a conserved conformational epitope of the Cap protein, represents a critical step forward in enabling large-scale epidemiological surveillance and informing targeted biosecurity interventions [1]. Complementary molecular diagnostic tools, including TaqMan-based quantitative real-time PCR and CRISPR/Cas12a-based visual detection methods, offer high sensitivity and specificity for detecting PiCV DNA in clinical specimens, even in the presence of extensive genetic diversity [9, 10]. The integration of serological and molecular testing strategies is essential for accurately assessing the infection status of individual birds and pigeon flocks, particularly given the high prevalence of subclinical infections [22, 27].

In summary, PiCV is a genetically diverse, globally distributed, and immunosuppressive pathogen of pigeons that continues to evolve through frequent recombination and point mutation. Its taxonomic placement within the genus Circovirus is well established, but the full extent of its genetic diversity, host range, and ecological interactions remains to be elucidated. The ongoing emergence of novel genotypes and the potential for spillover into non-columbiform hosts underscore the need for continued molecular surveillance, improved diagnostic tools, and the development of effective vaccines to mitigate the impact of PiCV on pigeon health and the global pigeon industry.

Molecular Pathogenesis and Host-Virus Interactions

Genomic Architecture and the Molecular Basis of Viral Diversity

The pathogenesis of pigeon circovirus (PiCV) is inextricably linked to the virus's compact, yet remarkably plastic, single-stranded DNA (ssDNA) genome. At approximately 2.0 to 2.1 kb, the genome is among the smallest known to infect vertebrates, encoding primarily two major open reading frames: the replication-associated protein (Rep) and the capsid protein (Cap) [2, 3, 8, 27]. This minimalist genetic economy, however, belies a sophisticated evolutionary strategy that underpins the virus's ability to persist, disseminate, and induce profound immunosuppression in its host. The Rep protein is essential for rolling-circle replication of the viral genome, while the Cap protein serves dual, interwoven roles: as the sole structural component of the virion and as the primary antigenic target of the host humoral immune response. It is within the cap gene that the most dramatic molecular variability is manifest, directly dictating the virus's interaction with the host [3, 7].

Extensive genetic characterization of PiCV strains across global pigeon populations has revealed that the cap gene exhibits nucleotide and amino acid homologies that can plummet to strikingly low levels, with reports of as little as 64.5% amino acid identity between certain isolates [2, 3]. This hypervariability is not uniformly distributed across the protein. Studies have pinpointed a hypervariable region spanning amino acid positions 30 to 120, where the majority of non-synonymous substitutions and indels are concentrated [2]. Critically, this region is juxtaposed against a relatively conserved domain at residues 140 to 180, which has been associated with strong antigenicity and is hypothesized to contain critical conformational epitopes [1, 2]. This conserved antigenic core explains the pan-genotypic reactivity observed with certain monoclonal antibodies, such as the 1G6-4C4 mAb developed against a group C strain, which can recognize Cap proteins from groups A through E, suggesting that despite immense diversity, a scaffold of functional and structural integrity is maintained [1].

Recombination as a Dominant Evolutionary and Pathogenic Driver

While point mutations contribute to the standing genetic variation, the dominant force driving PiCV evolution and engendering new pathogenic variants is recombination. The frequency of recombination events in PiCV is extraordinarily high, rivaling or exceeding that seen in other circoviruses [2, 3, 5, 7, 12]. Analyses of complete PiCV genomes from geographically disparate regions, including China, Australia, and Poland, have consistently identified multiple recombination breakpoints across the genome. For instance, studies of Chinese racing pigeon flocks detected 31 distinct recombination events [7, 17], while an investigation of Australian feral pigeons revealed extensive genetic admixture, implicating recombination in the generation of novel clades and even potential spillover events from other avian circoviruses [29]. This process is so pervasive that it can occur within a matter of weeks when birds from different origins are co-housed, as demonstrated in experimental One Loft Race (OLR) settings where recombinant genomes were detected within the first three weeks of co-mingling, coinciding with peak viremia [5, 12].

The functional consequences of recombination are profound. A recombination hotspot has been mapped to the 3’ end of the genome, the rep gene, and the intergenic region, whereas a notable cold spot exists within the cap gene [5, 12]. This suggests a strong selective pressure to maintain the structural integrity of the capsid, even as the replicase machinery is allowed to reassort and evolve. The emergence of novel recombinants is not merely an academic curiosity; it has direct implications for pathogenesis. The strain HLJ2024 from Heilongjiang, China, was identified as a likely recombinant between parental strains from Guangdong and Shaanxi provinces, carrying a signature mutation (Ile-to-Leu) at Cap residue 222 with predicted structural alterations [11]. Such recombination events can generate chimeric viruses with altered cell tropism, replication kinetics, or the capacity to evade pre-existing immunity in the host population [2, 3, 11].

The Molecular Lesion: Induction of B Lymphocyte Apoptosis and Humoral Immunosuppression

The central tenet of PiCV pathogenesis is its targeted destruction of the host’s humoral immune apparatus, a mechanism that has been experimentally substantiated. The principal pathological target is the bursa of Fabricius, the primary lymphoid organ for B cell maturation in birds. Histopathological examination consistently reveals severe lymphoid depletion, follicular atrophy, and the presence of characteristic botryoid intracytoplasmic inclusion bodies within bursal histiocytes [6, 16, 27, 33]. These inclusion bodies are, in fact, aggregates of non-enveloped virions, representing massive viral factories that ultimately lead to cell lysis.

The molecular mechanism driving this destruction has been clearly delineated: PiCV infection triggers a selective and profound induction of apoptosis in the B lymphocyte population. In a seminal study comparing PiCV-positive pigeons with clinical signs, asymptomatically infected birds, and uninfected controls, the percentage of IgM+ B cells in the spleen was nearly two-fold lower in clinically ill birds, and approximately 20% of these B lymphocytes were undergoing apoptosis [16]. Crucially, this apoptotic effect was not observed in the T CD3+ lymphocyte subpopulation, nor were there marked changes in CD4+ or CD8+ T cell proportions [16]. This selectivity explains the specific abrogation of humoral immunity. Further evidence from an experimental OLR study using droplet digital PCR to track viraemia and flow cytometry to assess lymphocyte subsets confirmed that the percentage of apoptotic splenic IgM+ B cells was approximately 40% higher in PiCV-infected birds compared to controls, directly linking viral replication in the bursa to B cell depletion [32].

The consequence of this targeted B cell lymphopenia is a state of profound humoral immunosuppression. The virus effectively disarms the host’s capacity to mount a robust antibody response, not only against itself but crucially against co-infecting pathogens. This is the molecular foundation of the "gateway" hypothesis, whereby PiCV acts as a primary immunosuppressive agent, facilitating secondary infections with pathogens such as Chlamydia psittaci, Escherichia coli, adenoviruses (Pigeon aviadenovirus A and Fowl aviadenovirus), rotaviruses, and columbid alphaherpesvirus 1 (CoHV1) [6, 14, 33, 36, 37]. The high viral load of PiCV in the bursa and lymphoid tissues is a direct correlate of disease severity, with clinically affected birds exhibiting viral copy numbers that are several orders of magnitude higher than those in subclinically infected cohorts [6, 16]. This is entirely consistent with a model where high-level viral replication drives massive B cell apoptosis, leading to a critical reduction in immunoglobulin-secreting cells and a failure of protective immunity.

Molecular Antagonism of Innate Immunity: Subversion of Interferon Signaling

The pathogenic strategy of PiCV extends beyond the direct killing of B cells to include a more subtle, molecular-level antagonism of the host's innate antiviral defenses. The type I interferon (IFN) pathway is a cornerstone of the antiviral response, and many viruses have evolved mechanisms to subvert it. Recent comparative research across the Circoviridae family has revealed that the capsid proteins of these viruses, including PiCV, possess immunomodulatory functions [31]. While the nuclear localization of the Cap protein is a conserved feature, its effect on IFN-β signaling is species-specific. Although the particular details for PiCV Cap are still being elucidated, it is known that the porcine circovirus type 2 (PCV2) capsid can potently inhibit the IFN-β promoter activation, and this family-wide functional conservation is highly suggestive [31].

Further direct evidence of PiCV’s impact on the interferon system comes from in vivo studies. Pigeons naturally and experimentally infected with PiCV show a distinct pattern of cytokine dysregulation. Treatment with recombinant pigeon interferon-alpha (PiIFN-α) has been shown to effectively suppress PiCV replication, reducing viral titers to undetectable levels. This antiviral effect was associated with the dominant upregulation of IFN-γ and Mx1 genes in the liver and spleen [34]. The fact that exogenous IFN-α can curb the infection suggests that the endogenous IFN response is either insufficient or actively suppressed by the virus. Indeed, in subclinically infected birds maintained under OLR conditions, the decline in viraemia and viral shedding in the later stages of infection partially correlated with the expression of IFN-γ and MX1 genes and the appearance of anti-PiCV antibodies [5]. This implies a delicate temporal balance: early exponential viral replication overwhelms initial innate defenses, and it is only after the adaptive immune system begins to engage (and the B cell compartment has been decimated) that viral load is brought under control. The virus's ability to dampen or delay this interferon response, potentially through its capsid protein, is a critical component of establishing a persistent, subclinical infection that can later erupt into full-blown YPDS when the host is stressed.

The Pathophysiological Cascade: From Subclinical Infection to YPDS and Coinfection Syndromes

The molecular events of B cell depletion and innate immune subversion culminate in a predictable pathophysiological cascade. PiCV infection is most commonly subclinical, with a high prevalence of asymptomatic carriers in breeding flocks, often exceeding 50-70% [5, 22, 27, 38]. In this state, the virus replicates at a low level, maintaining a persistent infection that can be intermittently shed. However, under the stress of racing, breeding, weaning, or co-mingling in OLR systems, viral replication can reactivate, leading to a surge in viraemia [5, 32].

This reactivation has devastating consequences. The peak in viraemia, which can occur as early as 14 days post-exposure or re-exposure, is directly associated with increased B cell apoptosis in the bursa [5, 32]. The resultant immunosuppression creates an immunological vacuum. This is the critical juncture where subclinical PiCV infection transitions to clinical young pigeon disease syndrome (YPDS), or more precisely, PiCV systemic disease (PiCV-SD) as defined by recent scholarship [8]. The syndrome is not a sequelae of PiCV infection alone, but rather a polymicrobial disease complex triggered by PiCV-induced immune failure.

The evidence for this is compelling and derived from numerous outbreak investigations. In a lethal outbreak in a zoo, concurrent infection with PiCV and Chlamydia psittaci genotype B was identified as the cause of sudden death in 58 birds. The PiCV infection was posited to have augmented the lethality of the chlamydiosis, as Chlamydia shedding is known to be activated by immunosuppression [14]. Similarly, a natural outbreak of CoHV1 in racing pigeons, which normally causes mild or subclinical disease, resulted in severe, fatal systemic disease in four birds that were heavily co-infected with PiCV. The viral copy numbers of both viruses were significantly higher in clinically affected pigeons, and the lesions were exacerbated [6]. This pattern repeats with Pigeon aviadenovirus A in Turkish pigeon flocks, where co-infection with PiCV was associated with severe clinical signs including anorexia, crop vomiting, and sudden death [33, 35]. Even in outbreaks of pigeon rotavirus A (RVA) genotype G18P[15], which is itself now considered a primary cause of classical YPDS, the vast majority of affected birds (15 out of 18 in one case series) were also co-infected with PiCV [37]. The ubiquitous presence of PiCV in these clinical scenarios strongly implicates it as a necessary co-factor for the expression of severe disease.

The final dimension of PiCV’s host interaction is its potential for cross-species transmission. PiCV has been detected in atypical hosts, including Eurasian collared-doves (Streptopelia decaocto) [25], a common raven (Corvus corax) with bursal lymphoid depletion [15], and even in ticks (Hyalomma asiaticum and Dermacentor nuttalli) collected from sheep and camels [28]. Most compellingly, PiCV Rep sequences have been obtained from clinically affected plumed whistling ducks, blue-billed ducks, and Australian magpies, providing clear evidence of natural spillover infections [26]. This capacity to infect non-columbid hosts, combined with its high mutation and recombination rates, raises significant concerns from a global biosecurity and One Health perspective. It suggests that PiCV may not be strictly host-specific and could pose a threat to other avian species, particularly in mixed-settings such as zoological collections or exhibition halls, where the virus can act as an immunosuppressive "key" unlocking susceptibility to a wide array of other pathogens [14, 31, 37]. The virus’s ability to survive in environmental matrices, as suggested by its detection in high-risk port environments in Belgium [30], underscores its potential for international spread and sustained transmission.

Epidemiology and Global Distribution of PiCV Infections

Pigeon circovirus (PiCV) represents one of the most pervasive viral pathogens affecting both domestic and feral pigeon populations (Columba livia domestica and Columba livia), with its global footprint extending across virtually all continents where Columbiformes are raised or occur naturally. Since its initial description in the early 1990s, PiCV has emerged as a pathogen of paramount significance to the pigeon industry, a recognition underscored by the virus’s consistent association with the immunosuppressive young pigeon disease syndrome (YPDS) and its capacity to facilitate severe secondary infections [8, 27]. The epidemiological profile of PiCV is characterized by remarkably high prevalence rates, profound genetic diversity driven by frequent recombination, and a broadening host range that challenges conventional assumptions about host specificity. As the sport of pigeon racing and the commercial meat pigeon industry continue to expand, particularly in regions such as China, where racing is considered a national sport, understanding the global distribution and transmission dynamics of PiCV has become an urgent prerequisite for designing effective biosecurity and control strategies [7, 17, 21].

Global Prevalence and Continental Distribution

The available epidemiological data, drawn from molecular surveys conducted over the past two decades, paint a consistent picture of PiCV as a hyperendemic infection in pigeon populations worldwide. In China, which has emerged as a focal point for PiCV research due to the explosive growth of the racing pigeon industry, multiple large-scale surveys have documented infection rates that range from substantial to near-ubiquitous. A landmark study examining 622 samples collected from 11 provinces or municipalities between 2016 and 2019 reported an overall sample-level positive rate of 19.3% (120/622), but a club-level prevalence of 59.0% (23/39), indicating that while the virus may not be detected in every individual bird sampled, it is present in the majority of racing pigeon lofts and clubs [7, 17, 21]. Even this figure likely underestimates the true burden, as a more recent study conducted across four Chinese cities employing sensitive molecular detection methods reported a staggering positive rate of 92.86% in the sampled pigeon flocks [2]. Similarly, an investigation of a single pigeon farm in Beijing that supplies experimental animals found PiCV infection confirmed in at least three tissue types from all 40 pigeons tested, yielding a 100% positivity rate at the farm level [3]. These findings collectively demonstrate that PiCV is not merely prevalent but is essentially endemic in Chinese pigeon populations, a situation that has serious implications for the use of pigeons as experimental models in biomedical research [3].

Outside of Asia, comparable prevalence patterns emerge. In Australia, a study of feral rock doves (Columba livia) in regional New South Wales revealed a PiCV infection rate of 76% by PCR, confirming that the virus circulates extensively even in wild, unmanaged populations [29]. This high carriage rate in asymptomatic feral birds has profound implications for transmission to domestic and racing pigeons, particularly given the propensity for feral pigeons to commingle with captive flocks in urban and peri-urban environments. In Europe, the epidemiological picture is equally concerning. A German study examining samples from 29 different breeders found that 65.5% of pigeon lofts were positive for PiCV, with the virus detected in 10.3% of individual cloacal swabs [38]. In Poland, extensive surveys have established PiCV as the most frequently diagnosed viral agent in pigeons, with seroprevalence studies indicating that approximately 70% of asymptomatic pigeons harbor anti-PiCV antibodies regardless of their infection status as determined by real-time PCR [22, 27]. This serological data is critical, as it suggests that the vast majority of pigeons, even those without detectable viral DNA in routine screening, have been exposed to PiCV at some point in their lives. In Turkey, a retrospective molecular investigation of samples collected from 16 private pigeon flocks between 2018 and 2021 identified PiCV genetic material in 25% of flocks, while also documenting the first detection of Columbid alphaherpesvirus 1 co-infection in Turkish pigeons [40]. The Middle East presents a similarly concerning scenario; a study in Iran examining 100 pigeons (80 clinically ill and 20 healthy) from 20 lofts in the Ahvaz region reported an extraordinary overall infection rate of 86%, with PiCV detected in both symptomatic and asymptomatic birds [4].

Recombination as a Driver of Genetic Diversity and Global Spread

A defining feature of PiCV epidemiology that distinguishes it from many other viral pathogens of poultry and companion birds is the extraordinary role of genetic recombination in shaping its evolution and global distribution. PiCV possesses a small, circular single-stranded DNA genome of approximately 2 kb, encoding primarily a replication-associated protein (Rep) and a capsid protein (Cap). Despite this minimal genetic architecture, the virus exhibits a degree of genetic plasticity that rivals much larger RNA viruses [27]. Recombination events in PiCV are not rare anomalies but rather a ubiquitous and fundamental mechanism of viral evolution. In the large-scale Chinese survey of racing pigeons, 31 recombination events were detected across the PiCV genomes obtained from positive samples [7, 17, 21]. A separate investigation of a single Beijing pigeon farm identified 13 recombination events in 18 out of 29 complete PiCV genomes, with recombination occurring between clades A/F, A/B, C/D, and B/D [3]. The frequency of these events is staggering when one considers that they represent independent genetic shuffling events occurring within a relatively small and confined population of birds.

The most detailed insights into recombination dynamics come from studies employing the One Loft Race (OLR) system, a rearing method wherein pigeons from multiple geographically dispersed lofts are housed together in a single facility to standardize training and competition conditions. This system, while designed to eliminate confounding variables in racing performance, creates an ideal epidemiological crucible for viral recombination [5, 12, 32]. In a landmark study using the OLR model, 388 complete PiCV genomes were recovered from 15 racing pigeons originating from five different breeding facilities over a six-week period of co-housing. Thirteen distinct genotypes were identified, and 25 recombination events were detected, with recombinants emerging predominantly during the first three weeks of the experiment, a timeframe that coincided precisely with the peak levels of viremia and viral shedding [5]. This temporal clustering is biologically significant, as it suggests that recombination is not merely a random process but is actively favored during periods of high viral replication and co-infection, when the probability of a single cell being infected by two distinct PiCV strains is maximized. A complementary study employing a similar OLR approach identified 13 recombination events among 178 PiCV genome sequences, with a recombination hotspot identified spanning the 3′ prime region, the rep gene, and the intergenic region, while the capsid protein-coding region was identified as a recombination cold spot [12]. The identification of a recombination hotspot in the rep gene is particularly noteworthy, as alterations in the replication-associated protein may directly influence viral fitness, host range, and transmissibility.

The global implications of this recombination-driven evolution are profound. PiCV strains circulating in geographically disparate regions are not genetically isolated but instead demonstrate extensive genetic admixture. Phylogenetic analyses have consistently revealed that strains from China, Australia, Poland, the United Kingdom, Belgium, Japan, and the United States cluster together within shared clades, indicating ongoing gene flow across vast distances [7, 26, 29]. The movement of racing pigeons for international competitions, the trade in breeding stock, and the translocation of birds by fanciers all serve as mechanisms for the physical transport of PiCV strains, bringing distinct viral lineages into contact and facilitating recombination. The Australian data are particularly instructive in this regard: phylogenetic analysis demonstrated that PiCV circulating in Australian feral pigeons formed two strongly supported monophyletic clades, one of which clustered with PiCV genomes from Poland, the United Kingdom, Belgium, China, and Japan, while the other basal clade was more closely related solely to Polish strains [29]. This pattern suggests multiple independent introductions of PiCV into Australia, likely through the importation of pigeons from Europe and Asia, followed by subsequent recombination between the introduced strains and resident viral lineages.

Host Range Expansion and Spillover Events

The epidemiological significance of PiCV extends beyond its impact on domestic pigeons, as emerging evidence indicates that the virus possesses a far broader host range than initially appreciated. Historically, PiCV was considered to be largely host-restricted to Columbiformes, but a growing body of data challenges this assumption. The first indication of a wider host range came from a study in the Czech Republic that identified PiCV DNA in Eurasian collared-doves (Streptopelia decaocto), demonstrating that the virus can naturally infect other columbid species beyond Columba livia [25]. More striking, however, is the evidence for spillover into non-columbiform hosts. In Australia, PiCV Rep sequences were recovered from clinically affected plumed whistling ducks (Dendrocygna eytoni), blue-billed ducks (Oxyura australis), and an Australian magpie (Gymnorhina tibicen), providing the first definitive evidence of natural PiCV spillover into waterfowl and passerine birds [26]. This represents a paradigm shift in our understanding of PiCV host range, as it suggests that the virus, like other circoviruses such as beak and feather disease virus (BFDV), may possess the genetic plasticity to adapt to novel hosts under appropriate ecological conditions.

Further evidence of host range expansion comes from the unexpected detection of PiCV in non-avian species. A metagenomic survey of ticks (Hyalomma asiaticum and Dermacentor nuttalli) collected from sheep and camels in Inner Mongolia, China, recovered a complete PiCV genome of 2,042 base pairs. Phylogenetic analysis confirmed that the circovirus identified in these ticks clustered unequivocally with known PiCV strains [28]. While the detection of PiCV DNA in ticks does not necessarily imply that ticks serve as competent biological vectors for viral replication and transmission, it raises the intriguing possibility that arthropods could act as mechanical vectors, facilitating the spread of PiCV between avian hosts or even across species boundaries. The detection of PiCV in a common raven (Corvus corax) presenting with bursal lymphoid depletion and opportunistic fungal infection further underscores the virus’s ability to infect non-columbid birds, although the clinical significance of such infections remains unclear [15].

Co-infection Dynamics and the Amplification of Disease

PiCV must be understood not as a pathogen that acts in isolation, but rather as a master manipulator of the host immune system that creates conditions favorable for a wide array of secondary invaders. The epidemiological data consistently demonstrate that PiCV infection is frequently accompanied by concurrent infections with other viral, bacterial, and parasitic agents, and that the presence of PiCV exacerbates the clinical outcomes of these co-infections. This phenomenon is central to the pathophysiology of YPDS, which is now recognized as a multifactorial syndrome in which PiCV-induced immunosuppression lowers the threshold for clinical disease caused by other pathogens [6, 27, 33].

The relationship between PiCV and Chlamydia psittaci is particularly well-documented and carries zoonotic implications of global significance. Chlamydia psittaci, the causative agent of psittacosis (ornithosis) in humans, is classified as a Category B bioterrorism agent by the U.S. Centers for Disease Control and Prevention (CDC) and is a notifiable disease under the World Organisation for Animal Health (WOAH) Terrestrial Animal Health Code. A seminal study conducted in Poland demonstrated that the prevalence of C. psittaci infection was two to three times higher in pigeons that were co-infected with PiCV compared to those infected with C. psittaci alone, a trend that was particularly pronounced in clinically ill birds [36]. The mechanistic basis for this synergy is rooted in PiCV’s profound immunosuppressive effects. PiCV infection leads to depletion of B lymphocytes through apoptosis, significantly impairing humoral immunity, while also altering the expression of key cytokines such as IFN-γ [16, 18, 34]. This creates an immunological vacuum in which C. psittaci, which is normally kept in check by an intact host immune response, can proliferate unchecked and reach shedding levels sufficient to cause environmental contamination and zoonotic transmission. The public health significance of this interaction cannot be overstated, given that pigeons serve as a major urban reservoir of C. psittaci and that human psittacosis outbreaks are frequently linked to exposure to pigeon feces.

The epidemiological interplay between PiCV and other avian viruses further amplifies disease burden. A lethal outbreak in a zoo involving 58 birds was attributed to concurrent infection with genotype B C. psittaci and PiCV, with histopathological examination revealing characteristic botryoid intracytoplasmic inclusion bodies consistent with circovirus infection in the bursa of Fabricius alongside chlamydial inclusions in macrophages, hepatocytes, and renal epithelium [14]. Similarly, natural co-infection with PiCV and pigeon aviadenovirus A has been documented in Turkish pigeon flocks, where the dual infection was associated with severe clinical manifestations including crop vomiting, watery diarrhea, anorexia, and sudden death, a clinical presentation that closely mirrors YPDS [33, 35]. In Australia, a natural outbreak of columbid alphaherpesvirus 1 (CoHV1) and PiCV co-infection in a flock of 60 racing pigeons resulted in four deaths within seven days of clinical onset. Quantitative PCR revealed that viral copy numbers for both PiCV and CoHV1 were significantly higher (p < 0.0001) in clinically affected pigeons compared to subclinically infected birds, suggesting that PiCV-induced immunosuppression may have permitted uncontrolled replication of CoHV1, leading to the development of severe lesions including suppurative stomatitis, pharyngitis, cloacitis, meningitis, and tympanitis [6]. The association between PiCV and pigeon rotavirus A (RVA) genotype G18P[15] is equally concerning; a case series from Germany documented disease outbreaks occurring 7–14 days after fancy pigeon shows, with PiCV detected in 15 of 18 examined pigeons, suggesting that PiCV carriage predisposes birds to severe RVA-associated disease [37].

Genotypic Diversity and Its Epidemiological Significance

The global distribution of PiCV is accompanied by extraordinary genetic diversity that complicates both diagnostic efforts and the development of universally effective control measures. Phylogenetic analyses based on complete genome sequences and cap gene sequences have consistently identified multiple distinct clades or genotypes, with the number of recognized clades expanding as more sequencing data become available. Early studies classified PiCV strains into six groups (A through F), but more recent and comprehensive analyses have revealed the existence of at least 12 to 13 distinct genotypes [2, 5, 12]. The large-scale Chinese survey of racing pigeons identified strains belonging to seven clades (A, B, C, E, G, H, and I) [7, 17, 21], while a study of four Chinese cities reported strains classified as types 1, 4, 6, and 11 [2]. The 29 complete genomes recovered from a single Beijing pigeon farm were divided into four clades: A (17.2%), B (10.4%), C (37.9%), and D (34.5%), demonstrating that even within a single farm, multiple clades circulate simultaneously [3]. This co-circulation of diverse genotypes within the same population is precisely the condition that favors recombination and the emergence of novel viral variants.

The genetic diversity of PiCV is most pronounced in the cap gene, which encodes the major structural protein. The amino acid sequences of Cap proteins among different PiCV strains can exhibit as little as 64.5% identity, a staggering degree of divergence for a single-stranded DNA virus [3]. Regions of the Cap protein corresponding to amino acid positions 30–120 have been identified as hypervariable, while positions 140–180 are relatively conserved and associated with strong antigenicity [2]. This pattern of variability has direct implications for serological diagnosis and vaccine development. The conserved antigenic domain spanning residues 140–180 has been exploited for the development of pan-genotypic detection methods, such as the recently described indirect competitive ELISA (icELISA) that employs a monoclonal antibody (1G6-4C4) targeting a conserved conformational epitope and capable of recognizing Cap proteins from PiCV groups A through E [1]. However, the high variability in other regions of Cap raises concerns about the potential for immune escape, particularly if subunit vaccines based on a single strain’s Cap protein are deployed widely.

Transmission Pathways and Risk Factors

Understanding the routes of PiCV transmission is essential for interpreting its global distribution patterns and for designing effective control interventions. PiCV is shed in high concentrations in both feces and oropharyngeal secretions, and the fecal-oral route is considered the primary mode of transmission [5, 27]. The virus is remarkably stable in the environment, a characteristic common to circoviruses, which are among the smallest and most physically robust known viruses. Environmental contamination of lofts, feed, water sources, and fomites plays a significant role in sustaining transmission within and between flocks. The OLR studies have provided critical quantitative data on viral shedding kinetics: peak levels of viremia and cloacal shedding were observed around day 14 post-exposure, followed by a gradual decline that corresponded temporally with the emergence of adaptive immune responses, including IFN-γ and MX1 gene expression and the production of anti-PiCV antibodies [5]. The fact that viral shedding declined but did not cease entirely in many birds indicates that PiCV can establish persistent or latent infections, with carriers serving as continuous sources of environmental contamination.

Management practices profoundly influence PiCV transmission dynamics. The attendance of pigeon shows and exhibitions has been identified as a significant risk factor for PiCV acquisition, with one German study demonstrating a strong relationship between show attendance and the occurrence of clinical signs in participating flocks [38]. The OLR system, in which pigeons from multiple lofts are brought together and housed communally, represents perhaps the highest-risk scenario for PiCV transmission and recombination. The epidemiological consequences of OLR rearing were starkly illustrated by a study that documented the emergence of recombinant PiCV strains within the first three weeks of co-housing, coinciding with peak viral shedding [5]. The authors of that study argued compellingly that the OLR system serves as an amplifier of PiCV diversity and that the practice warrants reconsideration from both an animal welfare and epidemiological perspective [5]. Vertical transmission has been suggested for PiCV, and the detection of viral DNA in dead-in-shell pigeon embryos provides indirect evidence for this route, although the relative contribution of vertical versus horizontal transmission to overall epidemiology remains to be quantified [39].

Diagnostic Methods and Their Impact on Epidemiological Understanding

The epidemiological data reviewed herein are heavily dependent on the diagnostic methods employed for PiCV detection, and advances in molecular and serological techniques have dramatically improved our ability to define the true prevalence and distribution of PiCV. Early studies relied on histopathological examination for the detection of characteristic botryoid intracytoplasmic inclusion

Clinical Manifestations and Young Pigeon Disease Syndrome (YPDS)

Pigeon circovirus (PiCV) infection presents a complex spectrum of clinical outcomes, ranging from subclinical viral carriage to a severe, often fatal, polymicrobial disease complex known globally as Young Pigeon Disease Syndrome (YPDS). The clinical manifestations of PiCV are inextricably linked to its primary pathological action: the induction of profound immunosuppression. This fundamental disruption of the host immune system creates a permissive environment for opportunistic secondary pathogens, thereby shaping the variable and often nonspecific clinical picture observed in affected flocks. Understanding this syndrome requires a detailed dissection of both the direct effects of PiCV and the cascading consequences of co-infections.

The Clinical Spectrum of PiCV Infection: From Subclinical to Systemic Disease

The clinical presentation of PiCV is not a monomorphic entity. As outlined in the seminal scoping review by Silva et al. [8], the literature has historically used the term "YPDS" in a diverse, non-standardized manner. To address this, a conceptual framework has been proposed differentiating PiCV subclinical infection (PiCV-SI) from PiCV systemic disease (PiCV-SD) [8]. PiCV-SI is characterized by the presence of viral DNA in the absence of overt clinical signs. This state is remarkably common; studies have detected PiCV in 70-86% of apparently healthy pigeons across various populations [4, 5, 22]. This asymptomatic carrier state, often involving persistent low-level viremia, is a critical epidemiological feature, as these birds serve as silent reservoirs for viral shedding and transmission [5, 12].

In stark contrast, PiCV-SD, frequently manifesting as YPDS, presents with a constellation of non-specific clinical signs. Affected birds, typically squabs and young birds (2-6 months of age), exhibit progressive lethargy, profound anorexia, and dramatic weight loss [2, 4, 13, 27, 33, 34]. Gastrointestinal signs are prominent and include crop stasis (a congested, fluid-filled crop), vomiting, and profuse watery to greenish diarrhea [4, 33, 37, 42]. Respiratory distress, characterized by dyspnea or open-mouth breathing, is also frequently observed, often linked to secondary bacterial or viral infections of the respiratory tract [2, 6, 27]. The mortality rate within an affected loft can be substantial, particularly when a virulent co-pathogen is involved [11, 13].

A direct correlation exists between the severity of clinical disease and the magnitude of the viral load. Quantitative studies have demonstrated that clinically affected pigeons harboring symptoms of YPDS possess PiCV viral loads that are up to 10,000-fold higher in the bursa of Fabricius compared to their subclinically infected counterparts [16]. Similarly, high viral copy numbers in the blood, oropharynx, and cloaca are strongly associated with clinical illness and mortality [6, 16]. The kinetics of viremia are also clinically relevant; in experimental settings mimicking a "One Loft Race" (OLR) system, a viremic peak is observed around 14 days post-exposure, followed by a gradual decline, which temporally correlates with the development of an adaptive immune response [5, 32]. This suggests that clinical disease is often an acute event coinciding with high viral replication, which may resolve as immunity develops, unless a secondary pathogen intervenes.

Pathophysiological Basis of Immunosuppression

The central pathogenic mechanism underlying the clinical manifestations of PiCV is the targeted depletion of B lymphocytes. Histopathological and flow cytometric analyses consistently reveal severe lymphoid depletion and atrophy of primary and secondary lymphoid organs, particularly the bursa of Fabricius, spleen, and thymus [6, 16, 27]. This depletion is driven by the induction of apoptosis specifically within the IgM+ B lymphocyte population. Stenzel et al. [16] demonstrated that PiCV-infected pigeons with clinical signs (group S) had nearly a twofold lower percentage of splenic B cells compared to uninfected controls, with approximately 20% of these cells undergoing apoptosis. Crucially, this pro-apoptotic effect is selective for B cells; no increased apoptosis was detected in the T CD3+ lymphocyte subpopulation [16]. Further work has confirmed that even in subclinical PiCV infections, the percentage of apoptotic splenic B cells can be approximately 40% higher than in uninfected birds, indicating that immunosuppression occurs on a spectrum beginning well before clinical signs are evident [32].

This specific destruction of B cells, the cornerstone of humoral immunity, renders the bird vulnerable to a host of secondary pathogens. The suppression of humoral immunity is further evidenced by a muted or delayed antibody response. For instance, while vaccination with PiCV recombinant capsid protein can elicit a humoral response, this response is significantly suppressed in birds that are already subclinically infected with PiCV, demonstrating a functional impairment of the B-cell compartment [18]. The virus also appears to interfere with cellular immunity, as PiCV infection can mask the potential cellular immune response to vaccination [18]. This complex interplay of humoral and cellular dysregulation explains why PiCV-infected pigeons are exquisitely susceptible to a wide range of viral, bacterial, and fungal agents.

YPDS as a Polymicrobial Syndrome

It is a critical clinical distinction that PiCV infection alone, particularly in immunocompetent juvenile or adult birds, may not always result in overt YPDS. A growing body of evidence positions PiCV as the necessary predisposing immunosuppressive agent, upon which a secondary infection triggers the full-blown clinical syndrome. This concept is supported by the difficulty in experimentally reproducing classic YPDS with PiCV alone [27, 42].

Multiple pathogens have been identified as key co-factors in the development of YPDS:

• Pigeon aviadenovirus A (PiAdV-A): Co-infection with PiAdV-A is a well-documented cause of severe YPDS outbreaks. Sahindokuyucu et al. [33, 35] isolated PiCV and PiAdV-A from pigeons exhibiting crop vomiting, diarrhea, anorexia, and sudden death. The histopathological finding of basophilic intranuclear inclusion bodies in degenerated hepatocytes confirmed the adenoviral component of the disease [33]. This co-infection is associated with a more rapidly fatal outcome than either virus alone.
• Columbid alphaherpesvirus 1 (CoHV1): In Australia, a natural outbreak of CoHV1 and PiCV co-infection resulted in a highly fatal disease in racing pigeons. Lesions were severe and included suppurative stomatitis, pharyngitis, cloacitis, meningitis, and tympanitis [6]. The presence of PiCV was hypothesized to have exacerbated the CoHV1-induced lesions. The viral loads of both pathogens were significantly higher in clinically affected pigeons, suggesting a synergistic relationship where PiCV-induced immunosuppression permits uncontrolled replication of CoHV1, and the resulting inflammation may, in turn, drive PiCV replication [6].
• Pigeon Rotavirus A (RVA): Recent investigations have strongly implicated pigeon RVA genotype G18P[15] as a primary trigger of the classical signs of YPDS, including anorexia, diarrhea, vomiting, and crop congestion [37, 42]. PiCV has been detected as a frequent co-infection in these cases, with up to 83% of birds in RVA outbreaks being PiCV-positive in one study [37]. This co-occurrence suggests that PiCV-induced immunosuppression may create a window of vulnerability for severe RVA disease, though RVA itself is a primary pathogen [42].
• Chlamydia psittaci: PiCV infection significantly increases the risk of severe chlamydiosis. A lethal concurrent outbreak in a zoo demonstrated that PiCV infection played a key role in augmenting the lethality of C. psittaci infection [14]. Epidemiological data indicate that pigeons co-infected with PiCV are two to three times more likely to be infected with C. psittaci than those without PiCV, underscoring the immunosuppressive role of PiCV in facilitating bacterial proliferation [36].
• Fungal and Bacterial Infections: The clinical presentation of YPDS is further complicated by secondary infections with opportunistic pathogens such as Escherichia coli, Staphylococcus spp., Aspergillus spp., and Candida spp., which exploit the immunocompromised state of the host [15, 27]. These secondary invaders can produce additional clinical signs, including respiratory rales, central nervous system signs, or localized abscesses.

Diagnostic Criteria and Clinical Pathological Correlates

Given the non-specific nature of clinical signs, definitive diagnosis requires laboratory confirmation. The clinical suspicion of YPDS should be raised in any loft experiencing poor racing performance, reduced fertility, increased mortality in young birds (especially 2-6 months of age), and birds presenting with a combination of lethargy, weight loss, and gastrointestinal distress [2, 4, 27]. Post-mortem examination often reveals characteristic lesions: atrophy of the bursa of Fabricius, which may be pale and reduced to a thin stalk, and splenic atrophy [6, 16, 27]. Histologically, the presence of botryoid, basophilic intracytoplasmic inclusion bodies (the "grape-like" clusters of virions) in bursal macrophages and histiocytes is pathognomonic for circovirus infection [6, 14, 16].

The clinical utility of molecular diagnostics, such as PCR and quantitative PCR, is paramount for confirming active infection and establishing viral load, which correlates with disease severity [6, 9, 16]. Serological assays, including the recently developed pan-genotypic indirect competitive ELISA (icELISA), provide a complementary tool for determining flock-level exposure and immune status [1]. However, it is vital to remember that a positive PiCV PCR from a cloacal swab of a live bird must be interpreted in the context of the high prevalence of subclinical infection [4, 5]. The diagnosis of PiCV as the causative agent of disease requires ruling out or identifying concurrent primary pathogens (e.g., RVA, PiAdV-A, CoHV1) and correlating a high viral load with clinical signs of immunosuppression and lymphoid depletion [6, 16, 41]. The standardized multiplex PCR for simultaneous detection of PiCV and adenovirus represents a significant advancement in the efficient diagnosis of this polymicrobial syndrome [41].

Advanced Diagnostic Methods: From PCR to Pan-Genotypic Serological Assays

The diagnostic landscape for Pigeon Circovirus (PiCV) has undergone a profound transformation over the past three decades, evolving from rudimentary histopathological identification of botryoid intracytoplasmic inclusion bodies within the bursa of Fabricius to a sophisticated arsenal of molecular and serological platforms. This evolution has been driven by two inescapable biological realities: the virus’s extraordinary genetic plasticity, characterized by extensive recombination and high mutation rates, and the complete absence of a permissive cell culture system for traditional virus isolation [8, 27]. The inability to propagate PiCV in vitro has rendered classical virological techniques – such as virus neutralization or plaque assays – entirely unavailable, forcing the field to innovate exclusively through molecular cloning, recombinant protein expression, and cutting-edge nucleic acid amplification technologies [13, 19, 23]. Consequently, the diagnostic armamentarium now spans from highly sensitive, quantitative polymerase chain reaction (qPCR) assays capable of detecting fewer than ten viral genome copies, to revolutionary pan-genotypic serological assays that overcome the profound antigenic diversity of the capsid protein. This section provides an exhaustive, mechanistic analysis of these advanced diagnostic modalities, critically evaluating their principles, validation, performance characteristics, and epidemiological utility in the context of PiCV’s global dissemination.

Conventional and Nested PCR Platforms: The Foundational Molecular Tool

The earliest molecular detection strategies for PiCV relied upon conventional end-point PCR, frequently employing a nested design to enhance sensitivity and specificity. The seminal work by Taras et al. (2003) [24] in the Czech Republic established one of the first nested PCR protocols targeting a 331-base pair fragment within the capsid protein gene. This approach proved instrumental in confirming PiCV presence beyond doubt, with sequencing of amplicons revealing a close phylogenetic relationship to the North-Irish isolate 7050 [24]. The nested PCR technique, wherein an initial round of amplification with outer primers is followed by a second round using internal primers, provides a crucial advantage in detecting low-copy-number templates that may be present in subclinically infected birds or in environmental samples such as fecal matter [39]. Indeed, Al-Baroodi and Al-Attar (2020) [39] employed a similar nested PCR strategy targeting the replication-associated protein (Rep) gene, demonstrating a 331-bp product in 66.7% of ill yearling pigeons from Mosul, Iraq, with the bursa of Fabricius yielding the highest detection rate (36.58%) among sampled tissues.

The utility of conventional PCR was rapidly extended to epidemiological surveys worldwide. In one of the largest cross-sectional studies to date, Wang et al. (2022) [7] screened 622 samples from racing pigeons across 11 Chinese provinces using a uniplex PCR targeting the cap gene, revealing a sample-level prevalence of 19.3% and a club-level prevalence of 59.0%. This stark discrepancy between individual and flock-level positivity underscores the enzootic nature of PiCV and the critical importance of appropriate sampling strategies. A subsequent study by Zhu et al. (2025) [2] amplified this finding, reporting a staggering 92.86% positive rate among 28 samples from four Chinese cities, further illustrating that conventional PCR, while robust, may significantly underestimate true prevalence when sampling is limited. The widespread adoption of PCR-based screening has also facilitated the detection of PiCV in non-traditional hosts, including Eurasian collared-doves (Streptopelia decaocto), Common ravens (Corvus corax), and even ticks (Hyalomma asiaticum and Dermacentor nuttalli) collected from sheep and camels in Inner Mongolia [15, 25, 28]. These findings, made possible by broad-spectrum PCR primers, indicate a far broader host range than previously appreciated, with implications for cross-species transmission and viral ecology.

However, conventional PCR suffers from several inherent limitations. The technique is qualitative or at best semi-quantitative, providing no information on viral load, which is critical for distinguishing active infection from residual nucleic acid or latent carriage. Moreover, the high genetic diversity of PiCV – with up to 13 distinct genotypes and nucleotide homologies in the cap gene ranging from 64.5% to 100% – poses a persistent challenge for primer design [2, 3, 5]. Primers that are too conserved may fail to amplify divergent strains, while primers that are too degenerate may yield non-specific products. To address this, multiplex PCR (mPCR) assays have been developed to simultaneously detect PiCV alongside other common pathogens implicated in Young Pigeon Disease Syndrome (YPDS). Santhanalakshmi et al. (2025) [41] standardized a multiplex PCR targeting the PiCV cap gene and the fowl adenovirus (FAdV) hexon gene, achieving distinct, reproducible amplicons without cross-reactivity. This approach not only reduces reagent costs and turnaround time but also provides a syndromic diagnostic capability that is essential for unraveling the multifactorial etiology of YPDS, where co-infections with PiCV, adenovirus, herpesvirus, and rotavirus are the rule rather than the exception [6, 14, 33, 35].

Quantitative Real-Time PCR: From SYBR Green to TaqMan and Droplet Digital PCR

The transition from end-point PCR to real-time quantitative PCR (qPCR) represented a quantum leap in PiCV diagnostics, enabling precise viral load determination, kinetic analysis of viremia, and assessment of shedding dynamics. Early qPCR systems for PiCV were based on SYBR Green I intercalating dye, which, while cost-effective, suffers from limited specificity due to its propensity to bind any double-stranded DNA, including primer-dimers and non-specific amplicons. Despite this limitation, SYBR Green-based assays have been successfully deployed for PiCV detection, capitalizing on melting curve analysis to differentiate specific products [22, 44]. Stenzel et al. (2017) [22] utilized SYBR Green qPCR targeting the Rep gene to classify 171 asymptomatic pigeons as PiCV-infected or uninfected, establishing the benchmark for subsequent serological correlation studies.

The development of TaqMan probe-based qPCR, however, has set a new standard for sensitivity and specificity. Nath et al. (2022) [9] designed a TaqMan assay targeting a highly conserved region of the Rep gene, achieving a limit of detection (LOD) of just two plasmid copies per reaction. This extraordinary sensitivity is essential for detecting the low viral loads often present in subclinically infected birds or in samples collected during the convalescent phase. The assay demonstrated 100% specificity when tested against a panel of 60 samples, including those positive for beak and feather disease virus (BFDV) and canine circovirus, and exhibited excellent reproducibility with intra-assay coefficients of variation (CV) ranging from 0.27% to 0.78% and inter-assay CVs from 1.84% to 2.87% [9]. Such precision is critical for longitudinal studies tracking the temporal dynamics of infection. In a remarkable application of this technology, Kwon et al. (2024) [5] and Dziewulska et al. (2025) [32] employed TaqMan qPCR to quantify PiCV viremia in young racing pigeons housed under One Loft Race (OLR) conditions. The studies revealed a distinct kinetic pattern: viremia peaked at day 14 post-housing, coinciding with the highest levels of viral shedding in cloacal swabs, followed by a progressive decline through day 35. This decline correlated temporally with the upregulation of interferon-gamma (IFN-γ) and MX1 gene expression, as well as the emergence of anti-PiCV antibodies, providing the first comprehensive in vivo evidence of immune-mediated viral clearance [5, 34].

For absolute quantification without the need for a standard curve, droplet digital PCR (ddPCR) has emerged as a powerful alternative. Dziewulska et al. (2025) [32] applied ddPCR to precisely quantify PiCV copy numbers in blood samples from experimentally housed pigeons. ddPCR partitions the sample into thousands of nanoliter-sized droplets, each of which undergoes an independent PCR reaction. By counting the fraction of positive droplets using Poisson statistics, ddPCR provides an absolute count of target molecules, unaffected by PCR efficiency variations that can plague traditional qPCR. This technology revealed that the peak viral load on day 14 reached a mean of approximately 4.2 log₁₀ copies/μL of blood, with a subsequent 1.5-log reduction by day 35 [32]. The enhanced precision of ddPCR is particularly valuable for detecting small changes in viral load over time, which is crucial for evaluating the efficacy of antiviral interventions such as pigeon interferon-alpha (PiIFN-α) administration [34] or probiotic supplementation with Bacillus velezensis [43].

Recombinase-Aided Amplification and CRISPR-Cas12a: Toward Point-of-Care Diagnostics

While qPCR and ddPCR offer unparalleled sensitivity and quantitation, their reliance on expensive thermal cyclers and skilled personnel limits their deployment in field settings or resource-limited laboratories. To address this gap, Wang et al. (2026) [10] developed a one-step, rapid visual detection method for PiCV by coupling recombinase-aided amplification (RAA) with CRISPR-Cas12a technology. RAA is an isothermal amplification method that operates at a constant temperature (typically 37–42°C), eliminating the need for thermal cycling. The amplified double-stranded DNA is then specifically recognized by a CRISPR RNA (crRNA) designed against a conserved region of the PiCV genome. Upon binding, the Cas12a nuclease is activated, unleashing its collateral, trans-cleavage activity against a fluorescent reporter probe, generating a visible signal that can be detected under blue light within 30 minutes [10].

The performance of this RAA-CRISPR assay was impressive: the LOD was determined to be 6.08 copies/μL, comparable to that of qPCR, and the assay showed no cross-reactivity with other pigeon pathogens, including paramyxovirus type 1 (PPMV-1), avian influenza (H9N2), and adenovirus. When applied to 40 clinical samples, the method achieved a 92.5% concordance rate with qPCR, and notably, it yielded a higher positive detection rate, likely due to its tolerance of inhibitors present in crude sample lysates [10]. This represents a paradigm shift in PiCV diagnostics, offering the potential for rapid, on-site screening at pigeon lofts, racing events, or quarantine stations, thereby enabling real-time biosecurity decisions. The WOAH (World Organisation for Animal Health) has increasingly emphasized the need for such portable diagnostic tools for emerging and re-emerging avian diseases, and the RAA-CRISPR platform aligns perfectly with these global surveillance goals.

Serological Assays: From Indirect ELISA to Pan-Genotypic Indirect Competitive ELISA

Serological detection of PiCV antibodies has historically been hampered by two major obstacles: the inability to produce native viral antigen due to the lack of a culture system, and the extreme antigenic diversity of the capsid protein (Cap), which is the primary target of the humoral immune response. Early efforts focused on expressing recombinant Cap (rCap) protein in Escherichia coli as a coating antigen for indirect ELISA (iELISA). This approach was pioneered by Stenzel et al. (2014, 2017, 2018) [20, 22, 27], who produced rCap using a GST fusion system and demonstrated its utility in detecting anti-PiCV antibodies in asymptomatic pigeons. Their results revealed that approximately 70% of pigeons tested positive for anti-PiCV antibodies regardless of their infection status, indicating widespread exposure. However, the iELISA format suffers from a critical limitation: it detects all antibodies that bind to the coated antigen, but the antigen itself is typically derived from a single PiCV genotype. Given that the Cap protein exhibits amino acid homologies as low as 64.5% between divergent strains, an iELISA based on one strain may fail to detect antibodies against heterologous genotypes, leading to substantial false-negative rates [1-3]. Indeed, Zhu et al. (2025) [2] demonstrated that the N-terminal region (amino acids 30–120) of Cap is hypervariable, while a relatively conserved region (amino acids 140–180) with strong antigenicity resides in the C-terminal domain. This suggests that any serological assay must either incorporate multiple antigens or target a truly conserved epitope to achieve pan-genotypic coverage.

The breakthrough came with the development of a pan-genotypic indirect competitive ELISA (icELISA) by Wang et al. (2025) [1]. This revolutionary assay is built upon a mouse monoclonal antibody (mAb), designated 1G6-4C4, which was raised against virus-like particles (VLPs) self-assembled from the Cap protein of a group C PiCV strain (SX10). Remarkably, mAb 1G6-4C4 was shown to recognize Cap proteins from PiCV strains belonging to groups A, B, C, D, and E, effectively spanning the known genetic diversity of the virus. The mechanism of this pan-genotypic reactivity is rooted in the mAb’s recognition of a conserved conformational epitope, likely formed by the three-dimensional folding of the Cap protein, rather than a linear peptide sequence that would be subject to amino acid substitution [1].

The icELISA format itself is elegantly designed to overcome the limitations of indirect detection. In this competitive system, a fixed amount of mAb 1G6-4C4 is pre-incubated with test serum samples. If the serum contains anti-PiCV antibodies, they will compete with the mAb for binding to the VLP-coated plate. The amount of mAb that binds to the plate is then measured using an anti-mouse IgG conjugate. Thus, a high signal indicates low competition (i.e., low antibody levels in the sample), while a low signal indicates strong competition (i.e., high antibody levels). This design eliminates the need for species-specific secondary antibodies and provides a more robust, quantitative readout. The assay exhibited exceptional specificity, showing no cross-reactivity with antibodies against PPMV-1, avian influenza (H9N2), fowl adenovirus type 4 (FAdV-4), or rotavirus [1]. When validated against 29 clinical serum samples, the icELISA detected a 51.72% antibody-positive rate compared to 44.82% for a conventional iELISA, yielding a concordance rate of 93.10%. The higher positivity rate of the icELISA suggests that it successfully captures antibodies against divergent PiCV strains that are missed by the genotype-restricted iELISA [1].

The epidemiological implications of this pan-genotypic icELISA are profound. Traditional PCR-based surveillance, while sensitive, only detects current or recent infection and provides no information on prior exposure. By combining PCR with icELISA, a comprehensive picture of PiCV epidemiology emerges: PCR-positive, seronegative birds may represent acute infections before seroconversion; PCR-positive, seropositive birds indicate active or recent infection with a developing immune response; and PCR-negative, seropositive birds reveal past exposure and potential immunological memory [1, 22]. The WHO and FAO have long advocated for such integrated diagnostic algorithms for the surveillance of viral diseases in animal populations, as they enable the differentiation of incidence from prevalence and provide critical data for mathematical modeling of transmission dynamics.

Advanced Applications: Viral Load Quantification, Recombination Kinetics, and Immunopathogenesis

The synergy between molecular and serological diagnostics has been leveraged to dissect the complex immunopathogenesis of PiCV infection. Stenzel et al. (2020) [16] combined qPCR viral load quantification with flow cytometry and serology to establish a direct correlation between PiCV copy numbers in the bursa of Fabricius and the severity of B lymphocyte apoptosis. Birds with high viral loads (10³–10⁴ times higher than subclinically infected birds) exhibited a nearly two-fold reduction in splenic B IgM+ cells, with approximately 20% of these cells undergoing apoptosis. Concurrently, anti-PiCV antibody levels were significantly lower in these birds, confirming that the virus actively suppresses humoral immunity [16]. This mechanistic insight, unattainable without precise viral load measurement, explains why PiCV predisposes pigeons to a myriad of secondary infections, including columbid alphaherpesvirus 1 (CoHV1), which causes severe stomatitis and encephalitis [6], and Chlamydia psittaci, a zoonotic pathogen of significant public health concern [14, 36].

The extraordinary recombination rate of PiCV, which has been documented in numerous studies involving whole-genome sequencing and phylogenetic analysis, also underscores the need for diagnostic methods that can capture evolving viral populations [5, 7, 11, 12, 29]. Khalifeh et al. (2021) [12] used deep sequencing of 178 PiCV genomes from pigeons housed in a single loft to identify a recombination hotspot spanning the 3′ end of the genome and the Rep gene, with a cold spot in the Cap-coding region. This suggests that the capsid protein, while diverse, is under purifying selection to maintain its structural and functional integrity, a finding that fortuitously supports the feasibility of a pan-genotypic serological assay targeting a conserved conformational epitope, as achieved by Wang et al. (2025) [1]. Furthermore, the detection of PiCV in ticks [28] and in environmental samples at international ports [30] using metagenomic sequencing highlights the need for continuous diagnostic surveillance to monitor the emergence of novel recombinants that may escape existing detection methods.

Conclusion of Section

The advanced diagnostic methods for PiCV have evolved from simple PCR detection to a sophisticated, multi-platform system that encompasses ultra-sensitive TaqMan qPCR, absolute quantification via ddPCR, rapid isothermal amplification with CRISPR-based visual readouts, and, most recently, a pan-genotypic competitive ELISA that finally overcomes the antigenic diversity of the capsid protein. These tools are not merely academic curiosities; they are indispensable for understanding the epidemiology, transmission dynamics, and immunopathogenesis of PiCV, and they form the cornerstone of any rational control program. The integration of molecular detection (PCR) for active infection with serological screening (icELISA) for past exposure provides a comprehensive diagnostic framework that is essential for the management of PiCV in racing and meat pigeon populations worldwide. As recombination and mutation continue to drive the evolution of this virus, the field must remain vigilant, adapting diagnostic strategies to capture the full extent of viral diversity and ensuring that the tools deployed in the field are as dynamic and resilient as the pathogen they are designed to detect.

Immune Response and Vaccine Development Challenges

The Immunopathological Hallmarks of PiCV Infection: B-Cell Depletion and Innate Immune Dysregulation

The pathogenesis of pigeon circovirus (PiCV) is fundamentally rooted in its capacity to subvert the host immune system, establishing a state of immunosuppression that predisposes birds to a cascade of secondary infections and the clinical manifestations collectively termed Young Pigeon Disease Syndrome (YPDS). The most critical and best-characterized immunological lesion induced by PiCV is the selective depletion and apoptosis of B lymphocytes, specifically the IgM+ B cell subpopulation. This phenomenon has been rigorously demonstrated through both natural infection studies and controlled experimental models. Stenzel et al. (2020) provided compelling evidence that PiCV-positive pigeons exhibiting clinical symptoms (group S) displayed nearly a two-fold lower percentage of splenic B IgM+ cells compared to healthy, PiCV-negative controls, with approximately 20% of these lymphocytes undergoing apoptosis [16]. Crucially, this apoptotic mechanism was highly specific; no increased apoptosis was detected in the T CD3+ lymphocyte subpopulation, highlighting a targeted attack on the humoral arm of the adaptive immune system [16]. This selective B cell lymphopenia has profound functional consequences. The bursa of Fabricius, the primary lymphoid organ for B cell maturation in birds, is a major site of PiCV replication, and the resulting lymphoid depletion leads to a compromised ability to generate a robust antibody response. This is reflected in the observation that PiCV viral loads were approximately one thousand to ten thousand times higher in clinically symptomatic birds (group S) than in asymptomatically infected or healthy birds, suggesting that the severity of infection is directly correlated with the degree of viral replication and the consequent immunosuppressive burden [16].

Further supporting this model, experimental studies using a One Loft Race (OLR) rearing system have elucidated the temporal dynamics of this immune dysregulation. Dziewulska et al. (2025) demonstrated that while the percentage of circulating IgM+ B lymphocytes in the blood remained relatively stable throughout a six-week observation period, there was a significant, approximately 40% increase in the percentage of apoptotic splenic IgM+ B cells in the PiCV-infected experimental group compared to uninfected controls [32]. This finding suggests that the primary site of B cell destruction is within the lymphoid tissues themselves, such as the spleen and bursa, rather than in peripheral blood, and that this local apoptosis drives the systemic immunosuppression. The peak of viremia, typically observed around day 14 post-exposure, appears to be a critical inflection point where innate immune mechanisms begin to exert control, concurrent with the initiation of a specific, albeit compromised, adaptive response [5, 32].

At the level of innate immunity, interferon-gamma (IFN-γ) and myxovirus resistance protein 1 (Mx1) play pivotal roles as early defenders. Stenzel et al. (2018) showed that immunization with recombinant capsid protein (rCP) induced a significantly higher expression of the IFN-γ gene from as early as two days post-vaccination, indicating that the cellular immune response, particularly the Th1 axis, is a component of the host's capacity to control PiCV replication [20]. In the context of natural infection dynamics under OLR conditions, a decrease in viremia and viral shedding was partially correlated with the expression of IFN-γ and Mx1 genes, as well as the dynamics of anti-PiCV antibody production [5]. This indicates that a coordinated innate and adaptive response is necessary, but the inherent defect in B cell survival often renders the humoral response inadequate, allowing for persistent or recurrent infection.

Viral Evasion Strategies: The Cap Protein and Interferon Antagonism

PiCV has evolved sophisticated molecular mechanisms to actively suppress the host's antiviral defenses, a strategy that is central to its success as an immunosuppressive pathogen. A landmark study by Kosaka et al. (2025) investigated the functional effects of Circoviridae capsid proteins on type I interferon (IFN) signaling. While the nuclear localization of these capsid proteins is a conserved feature across the family, their effects on IFN-β signaling were found to vary significantly by species. Critically, the study's findings highlight that the PiCV capsid protein (Cap), analogous to its counterpart in porcine circovirus type 2 (PCV2), plays a direct role in inhibiting the host's interferon response [31]. This interference with the type I IFN pathway, a cornerstone of the antiviral state, provides a mechanistic explanation for the ability of PiCV to establish persistent infections even in the face of an otherwise competent innate immune system. The inhibition of IFN-β signaling by the Cap protein undermines the expression of hundreds of interferon-stimulated genes (ISGs), effectively blunting the earliest wave of host defense and creating a permissive environment for viral replication and dissemination.

This viral antagonism is not absolute, however. The therapeutic potential of exogenous interferon has been confirmed in vivo. Santos et al. (2020) demonstrated that the administration of recombinant pigeon interferon alpha (PiIFN-α) was effective in reducing PiCV viral titers to undetectable levels in both naturally and experimentally infected pigeons. This treatment led to a significant upregulation of IFN-γ and Mx1 genes in the liver and spleen, suggesting that exogenous interferon can compensate for the virus-induced suppression of the endogenous pathway and restore a functional antiviral state [34]. These findings have dual implications: they confirm the central role of the IFN pathway in controlling PiCV, and they offer a potential therapeutic, rather than prophylactic, strategy to manage acute outbreaks, particularly in valuable racing or breeding stock. The fact that PiIFN-α demonstrated stability across varying temperatures and pH levels further suggests its practicality as a field treatment [34].

The Uncultivable Nature of PiCV and the Rationale for Subunit and VLP Approaches

The single most formidable obstacle in PiCV vaccine development is the complete inability to propagate the virus in conventional cell culture systems or embryonated eggs [1, 13, 19, 27]. This fundamental limitation precludes the use of classical inactivated or live-attenuated vaccine platforms, forcing the research community to rely exclusively on recombinant subunit or virus-like particle (VLP) technologies. The PiCV genome encodes two primary open reading frames: Rep (replication-associated protein) and Cap (capsid protein). The Cap protein is the sole structural protein and contains the primary neutralizing epitopes, making it the logical and only viable target for vaccine antigen design [1, 13, 19, 20].

To meet this challenge, several expression platforms have been successfully employed to produce recombinant PiCV Cap protein or self-assembling VLPs. Human embryonic kidney (HEK-293) cells, a mammalian expression system, have been used to produce PiCV rCap-VLPs with a spherical morphology and diameters of 12–26 nm, demonstrating strong immunogenicity in pigeons [13]. A baculovirus expression system in insect cells has also been utilized, yielding VLPs of 15–18 nm that induced specific antibodies when used to immunize mice with adjuvant [19]. Furthermore, the quest for a scalable, cost-effective production method has led to significant advancements in E. coli expression. Lai et al. (2014) achieved high-yield production of soluble, full-length PiCV Cap protein by optimizing fusion partners (GST-tag or Trx-His-tag), rare codon optimization, and using the BL21(DE3)-pLysS strain, reaching a production level of 394 mg/L, with 74.5% of the protein in a soluble form and demonstrating good antigenic activity against PiCV-infected sera [23]. This work is critical for the feasibility of large-scale manufacturing of a serological diagnostic antigen and a potential subunit vaccine.

Genetic Diversity and Antigenic Drift: A Moving Target for Vaccine Design

While the production of a recombinant Cap protein is technically feasible, the extraordinary genetic diversity of PiCV presents a colossal challenge for vaccine efficacy. The cap gene is the most variable region of the PiCV genome. Whole-genome sequencing studies across continents have consistently revealed staggeringly low levels of inter-strain amino acid homology in the Cap protein, ranging from as low as 64.5% to 100% [3, 7, 17, 21]. This level of diversity is unprecedented for a virus of this size and has profound implications for vaccine design. An analysis of 90 cap gene sequences from Chinese racing pigeons identified 28 unique amino acid substitutions in the Cap protein [7]. Phylogenetic analyses have repeatedly stratified PiCV strains into numerous clades (e.g., A through I, and new genotypes from Australia and China), with strains from a single geographic region frequently belonging to multiple distinct clades [2, 3, 7, 17, 21]. Wang et al. (2022) demonstrated that PiCV strains from China fell into seven distinct clades (A, B, C, E, G, H, and I), and Sun et al. (2026) identified a novel independent clade (GI) from a strain in Heilongjiang, further expanding the known diversity [7, 11].

This genetic plasticity means that a vaccine based on a single Cap sequence may provide only narrow, strain-specific protection. Critical to solving this is the identification of conserved immunogenic domains. Zhu et al. (2025) performed a detailed antigenicity analysis and identified a relatively conserved region from amino acids 140 to 180 of the Cap protein. This region was found to exhibit strong antigenicity, suggesting it contains epitopes that could be broadly recognized by antibodies generated against different PiCV genotypes [2]. This finding is a beacon of hope for pan-genotypic vaccine design. Similarly, the monoclonal antibody 1G6-4C4, developed by Wang et al. (2025), was shown to recognize the Cap of PiCV strains from groups A through E, likely targeting a conserved conformational epitope [1]. These data point toward the existence of a conserved antigenic core within the hypervariable Cap protein that, if effectively presented by a vaccine, could elicit cross-protective immunity.

The Compounding Challenge of Recombination

The already daunting genetic diversity of PiCV is further amplified by its high propensity for recombination, a common evolutionary driver among circoviruses [2, 3, 5, 11, 12, 17, 29]. Recombination events are rampant, with studies detecting 13 events in 18 out of 29 genomes from a single farm [3], 25 events in 388 genomes from an OLR experiment [5], and 31 events in Chinese racing pigeons [7, 17]. These recombination events are not random; they frequently involve the rep gene and the 3' intergenic region, with the cap gene often being a recombinant cold spot, though it is certainly not immune to it [12]. The OLR system, which houses pigeons from diverse origins in a single loft, acts as an ideal crucible for generating novel recombinants. Khalifeh et al. (2021) showed that recombinants emerged during the first three weeks of co-housing, coinciding with the peak of viremia and viral shedding [12]. Stenzel et al. (2024) confirmed this, showing that the OLR environment facilitated the rapid emergence of 13 different genotypes and 25 recombination events [5].

The implications for vaccine development are severe. Recombination can shuffle antigenic domains from different viral clades, potentially creating novel chimeric viruses that evade immunity generated against the parental strains. For example, Li et al. (2024) documented recombination events occurring between clades A/F, A/B, C/D, and B/D [3]. Sun et al. (2026) reported that the novel HLJ2024 strain likely arose from recombination between a major parent (GF17/GuangDong/2014) and a minor parent (TY2/SN/2016) from distant Chinese provinces, demonstrating that recombination can bridge inter-regional genetic gaps, facilitating the spread of new antigenic variants [11]. A successful vaccine strategy will therefore need to be robust enough to protect against this constantly shifting landscape of circulating and emergent recombinant strains.

Pre-Existing Immunity and the Blunted Vaccine Response in PiCV-Endemic Populations

A practical and often overlooked challenge in deploying a PiCV vaccine is the high prevalence of pre-existing subclinical infections in target populations. Serological surveys have consistently shown that the vast majority of pigeons, often exceeding 70%, are seropositive for PiCV, regardless of whether they are showing clinical signs [22]. This indicates that most birds are either actively infected or have been exposed, carrying a variable degree of pre-existing immunity that can complicate the response to a novel vaccine antigen.

Stenzel et al. (2019) directly addressed this issue in a landmark study comparing the immune response to PiCV recombinant capsid protein (PiCV rCP) in pigeons that were naturally infected (but asymptomatic) versus uninfected birds. The results were illuminating and concerning. While the PiCV rCP elicited an immune response in both groups, its nature and magnitude varied significantly based on infection status. In uninfected birds, vaccination led to a discernible increase in CD8 and IFN-γ gene expression. However, in the naturally infected pigeons, the baseline expression of CD8 and IFN-γ was already elevated due to the ongoing subclinical infection, and vaccination did not significantly boost these markers further [18]. This indicates that the subclinical infection "masks" the potential cellular immune response to the vaccine. More critically, the humoral response, as measured by seroconversion, was delayed and weaker in the infected group. While uninfected birds seroconverted by day 23 post-vaccination, the infected birds did not do so until day 39, and the overall level of anti-PiCV rCP IgY was suppressed [18]. This data suggests that pre-existing PiCV infection, with its associated B cell apoptosis and immune dysregulation, fundamentally impairs the bird's ability to mount a de novo humoral response to a vaccine, even one based on a relevant antigen.

Adjuvant Strategies and the Path Forward for Pan-Genotypic Protection

Given the inherent challenges of immunogenicity in a B cell-compromised host and the vast genetic diversity of the virus, the choice of adjuvant and delivery system is paramount. The first successful experimental PiCV VLP vaccine utilized a water-in-oil-in-water (W/O/W) adjuvant in conjunction with 100 µg of PiCV rCap-VLPs. This formulation induced specific antibodies, significant T-cell proliferation, and increased IFN-γ expression in the spleen. Critically, when vaccinated pigeons were experimentally infected with PiCV, they showed no detectable viral titer, indicating a high level of protective efficacy [13]. This study provides the foundational proof-of-concept that a protective immune response can be elicited.

The future of PiCV vaccine development lies in the integration of several strategic elements:

1. Pan-Genotypic Antigen Design: The vaccine antigen must move beyond a single Cap sequence. Strategies include the creation of chimeric VLPs displaying the conserved immunodominant region (amino acids 140-180) identified by Zhu et al. [2], or the development of a multi-epitope cocktail incorporating conserved epitopes from multiple clades. The identification of pan-genotypic monoclonal antibodies, such as 1G6-4C4 [1], provides a template for what a protective antibody response should resemble.
2. Augmenting Humoral Immunity: Adjuvants must be selected or designed to specifically overcome PiCV-induced B cell apoptosis. This may involve the inclusion of toll-like receptor (TLR) agonists that can directly stimulate B cells or the use of cytokines like BAFF (B-cell activating factor) to support B cell survival and differentiation.
3. Leveraging Innate Immunity: Given the ability of PiCV to suppress IFN signaling, administering the vaccine in conjunction with or sequenced after an initial dose of recombinant PiIFN-α could create a more favorable immunological milieu, potentially overcoming the blunted response seen in pre-infected birds [34].
4. Technology Platform and Logistics: The E. coli expression system offers a path to low-cost, high-volume production suitable for the poultry industry [23]. However, the VLP platforms (mammalian and baculovirus) may offer superior immunogenicity due to their particulate nature and repetitive antigen display [13, 19].

Ultimately, the route to a commercially viable and field-effective PiCV vaccine is fraught with biological, epidemiological, and logistical hurdles. The World Organisation for Animal Health (WOAH) recognizes the global economic burden of immunosuppressive diseases in poultry and ornamental birds, and the absence of a standardized vaccine for PiCV remains a critical gap in comprehensive disease management strategies. Any candidate will require rigorous field trials in naturally infected, high-density populations (such as OLR facilities) to validate its ability to reduce viral shedding, prevent the emergence of new recombinants, and lower the incidence of YPDS. The development of robust, pan-genotypic serological assays, such as the icELISA developed by Wang et al. [1], will be indispensable for monitoring vaccine-induced immunity and conducting the large-scale epidemiological surveillance necessary to evaluate any control program's success.

Biosecurity and Control Strategies in Racing and Meat Pigeon Industries

The implementation of effective biosecurity and control strategies for pigeon circovirus (PiCV) represents one of the most formidable challenges confronting the global racing and meat pigeon industries. The unique structural and operational characteristics of pigeon husbandry, particularly in racing establishments and commercial meat production facilities, create epidemiological conditions that profoundly complicate disease management. Unlike commercial poultry operations, where strict all-in-all-out principles, controlled environments, and standardized biosecurity protocols are routinely enforced, pigeon breeding operations often operate under management paradigms that inherently facilitate viral transmission and genetic diversification [27]. The racing pigeon sector, in particular, presents distinct challenges owing to the very nature of the sport, which necessitates the congregation of birds from disparate geographic origins and immunological backgrounds within single facilities, thereby creating ideal conditions for PiCV propagation, recombination, and inter-strain competition [5, 12, 32].

Diagnostic Surveillance as the Foundation of Control

Any rational biosecurity program must be predicated upon robust diagnostic capabilities, and the last decade has witnessed transformative advances in PiCV detection methodologies that now provide industry stakeholders with unprecedented tools for surveillance and intervention. The cornerstone of modern PiCV diagnostics is the quantitative polymerase chain reaction (qPCR), and the development of TaqMan-based platforms targeting the highly conserved rep gene has established detection limits as low as two plasmid copies per reaction, with 100% specificity and 100% sensitivity demonstrated against panels of known positive and negative samples [9]. This extraordinary sensitivity enables the detection of subclinical infections that would otherwise escape notice, a critical capability given that asymptomatic PiCV carriers are now recognized as the primary reservoir for viral maintenance within populations [16, 22]. The droplet digital PCR (ddPCR) methodology has further refined quantitative capabilities, as demonstrated in experimental One Loft Race (OLR) studies where precise viremia quantification revealed peak viral loads occurring at day 14 post-containment, followed by progressive decline coincident with adaptive immune maturation [32]. Such temporal data are invaluable for designing sampling regimens and interpreting diagnostic results within control programs.

The utility of molecular diagnostics has been enhanced by the development of multiplex platforms capable of simultaneously detecting PiCV alongside other pathogens implicated in Young Pigeon Disease Syndrome (YPDS). The standardization of multiplex PCR assays targeting the PiCV capsid gene and fowl adenovirus hexon gene, for instance, provides a rapid, cost-effective, and reproducible means of differential diagnosis that reduces both time and reagent consumption compared to uniplex approaches [41]. This capability is particularly relevant given the mounting evidence that PiCV-associated immunosuppression frequently manifests clinically only upon co-infection with secondary agents, including columbid alphaherpesvirus 1 (CoHV1), pigeon aviadenovirus A, Chlamydia psittaci, and rotavirus A genotype G18P[15] [6, 14, 33, 36-38]. The diagnostic landscape has been further revolutionized by the emergence of recombinase-aided amplification (RAA) coupled with CRISPR/Cas12a detection systems, which achieve limits of detection at 6.08 copies/µL and can be performed as rapid, on-site visual assays under blue light transillumination, obviating the need for sophisticated laboratory infrastructure [10]. This technology holds particular promise for field-based surveillance in resource-limited settings and for rapid screening at pigeon shows or auction facilities.

Serological Testing and the Imperative for Comprehensive Screening

While molecular detection of viral nucleic acid is indispensable for identifying active infections, the serological status of pigeon populations provides complementary information that is essential for comprehensive biosecurity management. The development of indirect competitive enzyme-linked immunosorbent assays (icELISA) employing monoclonal antibodies against the PiCV capsid protein represents a significant methodological breakthrough, as these assays demonstrate pan-genotypic reactivity across PiCV groups A through E by targeting a conserved conformational epitope, thereby overcoming the limitations of PCR-based approaches that may fail to detect highly divergent strains [1]. The icELISA format offers practical advantages over traditional indirect ELISA (iELISA), including reduced matrix interference and the capacity to detect antibodies regardless of the immunoglobulin isotype involved. Comparative evaluation of these platforms against clinical serum samples revealed antibody-positive rates of 51.72% and 44.82% for icELISA and iELISA, respectively, with concordance reaching 93.10%, confirming the suitability of icELISA for large-scale epidemiological surveillance in PiCV-endemic regions [1].

The importance of integrating serological and molecular testing cannot be overstated, particularly for the management of breeding flocks intended to remain PiCV-free. As demonstrated by Stenzel and colleagues, approximately 70% of asymptomatic pigeons tested positive for anti-PiCV antibodies regardless of their infection status as determined by real-time PCR, indicating that seropositivity is a poor predictor of current infection but an excellent marker of prior exposure [22]. Crucially, antibody levels, coefficients of variation, and standard deviations were significantly higher in PCR-positive birds compared to PCR-negative controls, suggesting that active viral replication drives a more heterogeneous and vigorous humoral response [22]. These findings underscore the necessity of employing both molecular and serological assays in parallel when evaluating the PiCV status of individual birds or populations destined for introduction into naive flocks. The development of high-yield E. coli expression systems for the PiCV capsid protein, achieving yields of 394.27 ± 26.1 mg/L with approximately 74.5% solubility, has rendered serological testing economically viable for routine screening applications [23].

Epidemiological Principles Shaping Biosecurity Interventions

The epidemiological data emerging from comprehensive surveillance studies provide an evidence base upon which rational biosecurity recommendations can be constructed. The prevalence of PiCV infection is consistently and alarmingly high across diverse geographic settings and production systems. In China, where pigeon racing has achieved the status of a national sport, sample-level PiCV positivity rates of 19.3% and club-level rates of 59.0% have been documented among racing pigeons across 11 provinces, with the virus detected in both clinically affected and apparently healthy birds [7, 17]. Even more striking are the findings from experimental farms in Beijing, where 100% of tested pigeons across three tissue types yielded PiCV DNA, and complete genome sequencing of 29 strains revealed nucleotide homologies ranging from 82.7% to 100% compared to references [3]. In Iran, prevalence rates of 86% have been reported among pigeons exhibiting YPDS-compatible clinical signs, with co-detection of beak and feather disease virus (BFDV) representing the first documentation of this pathogen in domestic pigeons [4]. Australian feral pigeon populations demonstrate comparable infection rates of 76%, and phylogenetic analyses have revealed extensive recombination and genetic admixture with other circoviruses, including evidence of natural spillover infection into aberrant hosts such as plumed whistling ducks, blue-billed ducks, and Australian magpies [26, 29]. The detection of PiCV genetic material in ticks (Hyalomma asiaticum and Dermacentor nuttalli) collected from sheep and camels in Inner Mongolia raises the possibility of arthropod-mediated transmission, although the epidemiological significance of this finding remains to be established [28].

The racing pigeon industry faces a particularly acute challenge owing to the widespread adoption of the One Loft Race (OLR) system, which was developed to standardize competitive conditions by housing pigeons from multiple origin lofts within a single facility [5, 32]. While this approach eliminates confounders related to differential training, nutrition, and husbandry, it simultaneously creates an epidemiological crucible wherein pathogens from diverse geographic regions and host genetic backgrounds are brought into intimate contact. Experimental studies simulating OLR conditions have yielded profoundly illuminating data regarding PiCV transmission dynamics. When 15 young racing pigeons from five different lofts, naturally infected with various PiCV variants, were housed together for six weeks, 388 complete PiCV genomes were recovered and 13 distinct genotypes were distinguished [5]. Recombination analysis revealed 25 events, with the majority of recombinants emerging during the first three weeks of co-housing, precisely coinciding with the peak of viremia and viral shedding [5, 12]. The viremia peak at day 14 was followed by a progressive decrease that partially corresponded with the expression of interferon-gamma (IFN-γ) and myxovirus resistance 1 (MX1) genes, as well as the dynamics of anti-PiCV antibody responses [5]. These observations carry profound implications for biosecurity: the initial weeks following the introduction of birds into communal housing represent a critical window for transmission and recombination, and interventions timed to this period may disproportionately impact overall infection dynamics.

Structural and Management Interventions

The structural design of pigeon housing facilities and the management practices employed within them constitute the first line of defense against PiCV introduction and propagation. Unlike conventional poultry houses, pigeon lofts often feature open-flight designs, communal perching and nesting areas, shared feeding and watering stations, and limited opportunities for effective cleaning and disinfection between occupancy cycles [27]. The specificity of pigeon breeding, as noted by Stenzel and Koncicki, often defies conventional biosecurity principles, which may explain the extraordinarily high prevalence of PiCV infections observed globally [27]. For racing lofts, the imperative to maintain birds in competitive condition frequently precludes the extended isolation periods that would be recommended from a strictly veterinary perspective. Nevertheless, certain fundamental interventions can be implemented to reduce transmission risk.

The compartmentalization of loft space into discrete units corresponding to age cohorts, health status categories, and origin sources represents a foundational biosecurity measure. Young pigeons, which are most susceptible to PiCV-induced immunosuppression and clinical disease, should be housed separately from adults to reduce the likelihood of horizontal transmission from asymptomatic carrier birds [16, 39]. The segregation of newly acquired birds for a minimum quarantine period of 4-6 weeks, with concurrent molecular and serological testing prior to introduction into the established flock, is strongly recommended [22]. Given that PiCV is shed in both feces and oropharyngeal secretions, the implementation of dedicated footwear and clothing protocols between housing units, coupled with the use of footbaths containing appropriate disinfectants, can reduce mechanical transmission. The selection of disinfectants with demonstrated efficacy against circoviruses, which are notoriously resistant to inactivation owing to their small, non-enveloped structure and circular single-stranded DNA genome, requires careful consideration. While specific data on PiCV disinfection are limited, extrapolation from porcine circovirus type 2 (PCV2) literature suggests that oxidizing agents, aldehydes, and chlorine-based compounds may be more effective than quaternary ammonium compounds alone.

Control of Virus Introduction at Shows and Competitions

Pigeon shows, exhibitions, and racing events represent high-risk settings for PiCV transmission, and the epidemiological data now available provide compelling evidence for the implementation of targeted control measures at these gatherings. A retrospective molecular investigation conducted in Turkey between 2018 and 2021 detected PiCV genetic material in 25% of sampled pigeon flocks, with CoHV1 identified in one flock and co-infection documented for the first time in that country [40]. More specifically, studies of pigeon rotavirus A outbreaks following fancy pigeon shows in Germany revealed that disease episodes occurred 7-14 days after shows, with PiCV detected in 15 of 18 affected pigeons [37]. The relationship between show attendance and infection risk has been quantitatively established: a survey of 29 German breeders demonstrated a strong relationship between show participation and the occurrence of clinical signs, with a higher prevalence of pigeon rotavirus in exhibited animals confirming that exhibitions serve as risk factors for pathogen transmission [38]. These findings suggest that pre-show health certification requirements, including molecular testing for PiCV, could substantially reduce the introduction of infected birds into exhibition environments.

The racing pigeon industry faces additional challenges arising from the international movement of birds for competition and breeding purposes. The detection of cross-border contaminants, including PiCV strains originating from Belgium, in environmental samples collected at international ports of entry underscores the potential for global dissemination of viral variants through the racing pigeon trade network [30]. This observation highlights the relevance of international health regulations and the potential role of organizations such as the World Organisation for Animal Health (WOAH) in establishing standards for the international movement of pigeons. While PiCV is not currently listed as a notifiable disease by WOAH, the economic impact of PiCV-associated disease on the racing and meat pigeon industries, coupled with the virus's capacity for rapid evolution through recombination, may warrant reconsideration of this status.

Vaccination Strategies: Progress and Obstacles

The development of effective vaccination strategies against PiCV has been hampered by a fundamental biological obstacle: the inability to propagate PiCV in cell culture systems, which precludes the production of traditional inactivated or attenuated vaccines [13, 19, 27]. This limitation has necessitated a paradigm shift toward subunit vaccine approaches employing recombinant capsid protein (rCP) or virus-like particles (VLPs) produced in heterologous expression systems. The PiCV capsid protein, encoded by the cap gene, is the sole structural protein of the virion and contains the immunodominant epitopes responsible for eliciting neutralizing antibody responses [2, 20]. The self-assembly of recombinant Cap into VLPs, demonstrated using both mammalian (HEK-293) and baculovirus expression systems, yields particles measuring 12-26 nm in diameter that closely mimic the native virion architecture while lacking infectious genetic material [13, 19].

The immunogenicity of PiCV rCP has been definitively established through controlled vaccination trials in carrier pigeons. Subcutaneous immunization with 100 µg of PiCV rCap-VLPs emulsified in water-in-oil-in-water (W/O/W) adjuvant induced specific anti-PiCV antibodies, significantly enhanced T-cell proliferation in the spleen, and upregulated IFN-γ expression compared to unvaccinated controls [13]. Importantly, experimentally infected pigeons that received the VLP vaccine showed no detectable viral titer, providing proof-of-concept for the protective efficacy of this approach [13]. The baculovirus-produced VLPs, when combined with adjuvant and administered intramuscularly to BALB/c mice, induced specific antibodies against the Cap protein, confirming the immunogenicity of the recombinant product across species [19].

However, the translation of these promising findings into practical vaccination protocols for racing and meat pigeons faces several unresolved challenges. The high prevalence of subclinical PiCV infection in pigeon populations worldwide means that most birds targeted for vaccination will already be infected at the time of immunization [27]. A critical study investigating the immune response to PiCV rCP vaccination in naturally infected versus uninfected pigeons revealed that infection status significantly modulated vaccine responsiveness. While both groups exhibited seroconversion following vaccination, the expression of CD8 and IFN-γ genes was higher in infected birds irrespective of vaccination, suggesting that pre-existing PiCV infection masks the potential cellular immune response to the vaccine and leads to suppression of humoral immunity [18]. These findings indicate that effective vaccination programs must be implemented in naive populations or during periods of minimal viral circulation, strategies that may be difficult to achieve in endemic settings.

The genetic diversity of PiCV presents an additional obstacle to vaccine development. Sequence analysis of the cap gene from PiCV strains circulating globally has revealed nucleotide homologies ranging from 71.9% to 100% and amino acid homologies from 71.7% to 100%, with the N-terminal region spanning amino acids 30-120 exhibiting the greatest frequency of variation [2, 7, 17]. Phylogenetic analyses have delineated at least 12-13 distinct PiCV genotypes, with multiple clades often co-circulating within the same geographic region or even within the same loft [2, 5, 7, 17]. This genetic heterogeneity raises legitimate concerns regarding the breadth of protection afforded by monovalent rCP or VLP vaccines. Encouragingly, antigenicity analysis has identified amino acids 140-180 of the Cap protein as relatively conserved and strongly antigenic, suggesting that this region may serve as a candidate for broadly protective vaccine design [2]. The availability of pan-genotypic monoclonal antibodies that recognize conserved conformational epitopes across PiCV groups A through E further supports the feasibility of developing vaccines capable of eliciting cross-protective immunity [1].

Immunomodulatory and Adjunctive Therapeutic Approaches

Beyond active immunization, several adjunctive strategies for controlling PiCV infection have been explored, including the use of interferon therapy and probiotic supplementation. The antiviral activity of pigeon interferon alpha (PiIFN-α) has been demonstrated both in vitro and in vivo. Recombinant PiIFN-α, when administered to pigeons naturally and experimentally infected with PiCV, resulted in no detectable viral titers in treated birds, with the antiviral effect accompanied by dominant upregulation of IFN-γ and MX1 gene expression in liver and spleen tissues [34]. Importantly, PiIFN-α demonstrated stability across a range of temperature and pH conditions, maintaining antiviral activity for at least four hours under varying environmental exposures [34]. These findings suggest that exogenous interferon administration may provide a therapeutic tool for reducing viral load during outbreaks or for protecting high-value racing pigeons during periods of increased exposure risk, such as prior to competitions.

Probiotic supplementation represents another immunomodulatory approach with potential relevance to PiCV control. Bacillus velezensis, when administered as a probiotic to PiCV-infected pigeons, enhanced the expression of immune regulatory genes, suggesting that modulation of the intestinal microbiota may augment antiviral immune responses [43]. While the precise mechanisms underlying this effect require further elucidation, the approach aligns with broader trends in veterinary medicine toward the use of probiotics as immunostimulatory feed additives.

The Imperative for Integrated Control Programs

The control of PiCV in racing and meat pigeon industries cannot be achieved through any single intervention but rather requires the integration of multiple complementary strategies tailored to the specific operational context. For commercial meat pigeon operations, where birds are typically housed in large, confined populations and marketed at relatively young ages, the emphasis should be on maintaining PiCV-free breeding flocks through rigorous testing protocols, strict biosecurity, and vaccination of replacement stock if and when licensed vaccines become available. The observation that PiCV viral loads are approximately one thousand to ten thousand times higher in clinically symptomatic pigeons compared to subclinically infected or PiCV-negative birds provides a quantitative basis for culling decisions and quarantine stringency [16]. For racing pigeon establishments, where the economic and emotional value of individual birds is extraordinarily high and where management practices are constrained by competitive imperatives, the focus should be on risk mitigation through pre-competition health screening, isolation of newly acquired birds, and strategic use of immunomodulatory agents during high-risk periods such as OLR events.

The detection of PiCV in environmental samples at international ports of entry and in ticks collected from livestock animals complicates the biosecurity picture and raises questions about transmission routes that extend beyond direct bird-to-bird contact [28, 30]. The potential for fomite-mediated transmission, vector-borne spread, and spillover from wild avian reservoirs must be considered in comprehensive risk assessments. The demonstration of natural PiCV spillover infection in non-columbiform species, including ducks and passerines, suggests that the host range of PiCV may be broader than previously appreciated and that wildlife reservoirs could contribute to viral maintenance and reintroduction into domestic populations [15, 26]. The presence of PiCV in a common raven (Corvus corax) presenting with bursal lymphoid depletion and

References

[1] Wang W, Xiao S, Zhang M, Liu J, Tian J, Chang C, et al.. A pan-genotypic indirect competitive ELISA for serological detection of pigeon circovirus antibodies. Frontiers in Microbiology. 2025. DOI: https://doi.org/10.3389/fmicb.2025.1612715

[2] Zhu R, Luo L, Shi Z, Chen Y, Xu J, Li G, et al.. Epidemiology, genetic diversity and evolution of pigeon circovirus. Poultry Science. 2025. DOI: https://doi.org/10.1016/j.psj.2025.104928

[3] Li X, Wang S, Li W, Wang S, Qin X, Wang J, et al.. Investigating pigeon circovirus infection in a pigeon farm: molecular detection, phylogenetic analysis and complete genome analysis. BMC Genomics. 2024. DOI: https://doi.org/10.1186/s12864-024-10303-4

[4] Shabani H, Talazadeh F, Kaydani G, Seifi M. Sequencing of pigeon circovirus and the first report of identification of beak and feather disease virus in clinical specimens of domestic pigeons. Veterinary Research Forum. 2024. DOI: https://doi.org/10.30466/vrf.2023.2002023.3879

[5] Stenzel T, Dziewulska D, Łukaszuk E, Custer JM, Koch MDD, Kraberger S, et al.. The pigeon circovirus evolution, epidemiology and interaction with the host immune system under One Loft Race rearing conditions. Scientific Reports. 2024. DOI: https://doi.org/10.1038/s41598-024-64587-3

[6] Nath B, Das S, Tidd N, Das T, Forwood J, Raidal S. Lesions and viral loads in racing pigeons naturally coinfected with pigeon circovirus and columbid alphaherpesvirus 1 in Australia. Journal of Veterinary Diagnostic Investigation. 2023. DOI: https://doi.org/10.1177/10406387231156839

[7] Wang H, Gao H, Jiang Z, Shi L, Zhao P, Zhang Y, et al.. Molecular detection and phylogenetic analysis of pigeon circovirus from racing pigeons in Northern China. BMC Genomics. 2022. DOI: https://doi.org/10.1186/s12864-022-08425-8

[8] Silva BB, Urzo ML, Encabo JR, Simbulan AM, Lunaria AJD, Sedano S, et al.. Pigeon Circovirus over Three Decades of Research: Bibliometrics, Scoping Review, and Perspectives. Viruses. 2022. DOI: https://doi.org/10.3390/v14071498

[9] Nath B, Das S, Das T, Forwood J, Raidal S. Development and applications of a TaqMan based quantitative real-time PCR for the rapid detection of Pigeon circovirus (PiCV).. Journal of Virological Methods. 2022. DOI: https://doi.org/10.2139/ssrn.4145120

[10] Wang C, Tang M, Liu L, Feng E, Luo G, Wu D, et al.. Establishment of a One-Step Rapid Visual Detection Method for Pigeon Circovirus Based on the RAA-CRISPR/Cas12a Assay.. Veterinary Sciences. 2026. DOI: https://doi.org/10.3390/vetsci13020206

[11] Sun J, Miao Y, Lan S, Zhao J, Dong W, Hu J, et al.. Whole-genome characterization and phylogenetic analysis of pigeon circovirus in racing pigeons from Heilongjiang, China. Frontiers in Veterinary Science. 2026. DOI: https://doi.org/10.3389/fvets.2025.1685178

[12] Khalifeh A, Kraberger S, Dziewulska D, Varsani A, Stenzel T. A Pilot Study Investigating the Dynamics of Pigeon Circovirus Recombination in Domesticated Pigeons Housed in a Single Loft. Viruses. 2021. DOI: https://doi.org/10.3390/v13060964

[13] Huang H, Silva BB, Tsai S, Tsai C, Tyan Y, Lin T, et al.. Immunogenicity and Protective Activity of Pigeon Circovirus Recombinant Capsid Protein Virus-Like Particles (PiCV rCap-VLPs) in Pigeons (Columba livia) Experimentally Infected with PiCV. Vaccines. 2021. DOI: https://doi.org/10.3390/vaccines9020098

[14] Chen W, Teng C, Shih C, Huang W, Jiang Y, Chang H, et al.. Investigation of Lethal Concurrent Outbreak of Chlamydiosis and Pigeon Circovirus in a Zoo. Animals. 2021. DOI: https://doi.org/10.3390/ani11061654

[15] Pesant M, Ferrell ST, Köszegi M, Baby V, Saint-Sauveur VG, Tejada CV, et al.. Complete genome sequence of a Circovirus pigeon strain in lymphocyte-depleted bursa of Fabricius of a Common Raven (Corvus corax). Microbiology Resource Announcements. 2024. DOI: https://doi.org/10.1128/mra.00378-24

[16] Stenzel T, Dziewulska D, Tykałowski B, Koncicki A. The Clinical Infection with Pigeon Circovirus (PiCV) Leads to Lymphocyte B Apoptosis But Has No Effect on Lymphocyte T Subpopulation. Pathogens. 2020. DOI: https://doi.org/10.3390/pathogens9080632

[17] Wang H, Gao H, Jiang Z, Shi L, Zhao P, Zhang Y, et al.. Molecular detection and phylogenetic analysis of pigeon circovirus from racing pigeons in China during 2016-2019. . 2021. DOI: https://doi.org/10.22541/AU.162276617.76492115/V1

[18] Stenzel T, Dziewulska D, Śmiałek M, Tykałowski B, Kowalczyk J, Koncicki A. Comparison of the immune response to vaccination with pigeon circovirus recombinant capsid protein (PiCV rCP) in pigeons uninfected and subclinically infected with PiCV. PLoS ONE. 2019. DOI: https://doi.org/10.1371/journal.pone.0219175

[19] Gai W, Zheng W, Zhao Z, Wong G, Sun P, Yan L, et al.. Assembly of pigeon circovirus-like particles using baculovirus expression system.. Microbial Pathogenesis. 2019. DOI: https://doi.org/10.1016/j.micpath.2019.103905

[20] Stenzel T, Dziewulska D, Tykałowski B, Śmiałek M, Kowalczyk J, Koncicki A. Immunogenicity of Pigeon Circovirus Recombinant Capsid Protein in Pigeons. Viruses. 2018. DOI: https://doi.org/10.3390/v10110596

[21] Wang H, Gao H, Jiang Z, Shi L, Zhao P, Zhang Y, et al.. Molecular detection and phylogenetic analysis of pigeon circovirus in China during 2016-2019. . 2020. DOI: https://doi.org/10.22541/au.160492711.19797943/v1

[22] Stenzel T, Woźniakowski G, Pestka D, Choszcz D, Tykałowski B, Śmiałek M, et al.. Application of pigeon circovirus recombinant capsid protein for detecting anti‐PiCV antibodies in the sera of asymptomatic domestic pigeons and the potential use of a combination of serological and molecular tests for controlling circovirus infections in pigeon breeding flocks. Poultry Science. 2017. DOI: https://doi.org/10.3382/ps/pew266

[23] Lai G, Lin Y, Tsai Y, Lien Y, Lin M, Chen H, et al.. High yield production of pigeon circovirus capsid protein in the E. coli by evaluating the key parameters needed for protein expression. BMC Veterinary Research. 2014. DOI: https://doi.org/10.1186/1746-6148-10-115

[24] Taras L, Kubíček O, Juranová R, Jurajda V. The First Demonstration of Pigeon Circovirus Infection in the Czech Republic Based on Histological Testing and Nested PCR. Acta Veterinaria Brno. 2003. DOI: https://doi.org/10.2754/AVB200372040577

[25] Kubíček O, Taras L. Incidence of Pigeon Circovirus in Eurasian Collared-Dove ( Streptopelia decaocto ) Detected by Nested PCR. Acta Veterinaria Brno. 2005. DOI: https://doi.org/10.2754/AVB200574030361

[26] Nath B, Das T, Peters A, Gupta S, Sarker S, Forwood J, et al.. Australasian Pigeon Circoviruses Demonstrate Natural Spillover Infection. Viruses. 2023. DOI: https://doi.org/10.3390/v15102025

[27] Stenzel T, Koncicki A. The epidemiology, molecular characterization and clinical pathology of circovirus infections in pigeons – current knowledge. Veterinary Quarterly. 2017. DOI: https://doi.org/10.1080/01652176.2017.1325972

[28] Kong Y, Yan C, Zhang G, Cai Y, He B, Li Y. Detection of pigeon circoviruses in ticks of sheep and camels in Inner Mongolia, China. bioRxiv. 2021. DOI: https://doi.org/10.1101/2021.06.09.447674

[29] Sarker S, Das S, Ghorashi S, Forwood J, Raidal S. Pigeon circoviruses from feral pigeons in Australia demonstrate extensive recombination and genetic admixture with other circoviruses. Avian Pathology. 2019. DOI: https://doi.org/10.1080/03079457.2019.1629391

[30] He X, Zhang R, Dong J, Zhen W, Zhu L, Ren J, et al.. A metagenomic approach for microbial risk assessment and source attribution in high-risk ports of entry environments. Biosafety and Health. 2025. DOI: https://doi.org/10.1016/j.bsheal.2025.07.001

[31] Kosaka A, Huang C, Lu Z, Hsing H, Choonnasard A, Ringo RS, et al.. Divergent Effects of Circoviridae Capsid Proteins on Type I Interferon Signaling. Pathogens. 2025. DOI: https://doi.org/10.3390/pathogens14010068

[32] Dziewulska D, Tykałowski B, Łukaszuk E, Stenzel T. The course of pigeon circovirus infection in young pigeons experimentally kept under conditions mimicking the One Loft Race rearing system. Journal of Veterinary Research. 2025. DOI: https://doi.org/10.2478/jvetres-2025-0009

[33] Sahindokuyucu I, Turkmen MB, Sumer T, Elhag AE, Alçığır M, Yazici Z, et al.. First detection and molecular characterisation of a pigeon aviadenovirus A and pigeon circovirus co‐infection associated with Young Pigeon Disease Syndrome (YPDS) in Turkish pigeons (Columba livia domestica). Veterinary Medicine and Science. 2021. DOI: https://doi.org/10.1002/vms3.662

[34] Santos HM, Chen C, Tsai C, Hsish YC, Chung FC, Tyan Y, et al.. Influence of pigeon interferon alpha (PiIFN-α) on pigeon circovirus (PiCV) replication and cytokine expression in Columba livia.. Veterinary Microbiology. 2020. DOI: https://doi.org/10.1016/j.vetmic.2020.108591

[35] Sahindokuyucu I, Turkmen MB, Anteplioğlu T, Alçiği̇r E, Yazici Z, Barry G, et al.. Young Pigeon Disease Syndrome (YPDS) in Turkish Pigeons (Columba livia domestica) stemming from coinfection with Pigeon aviadenovirus A and Pigeon circovirus: The first isolation and molecular characterization. . 2020. DOI: https://doi.org/10.22541/au.160434016.62202007/v1

[36] Stenzel T, Pestka D, Choszcz D. The prevalence and genetic characterization of Chlamydia psittaci from domestic and feral pigeons in Poland and the correlation between infection rate and incidence of pigeon circovirus.. Poultry Science. 2014. DOI: https://doi.org/10.3382/ps.2014-04219

[37] Schmidt V, Kümpel M, Cramer K, Sieg M, Harzer M, Rückner A, et al.. Pigeon rotavirus A genotype G18P[17]-associated disease outbreaks after fancy pigeon shows in Germany – a case series. Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere. 2021. DOI: https://doi.org/10.1055/a-1339-0366

[38] Harzer M, Heenemann K, Sieg M, Vahlenkamp T, Freick M, Rückner A. Prevalence of pigeon rotavirus infections: animal exhibitions as a risk factor for pigeon flocks. Archives of Virology. 2020. DOI: https://doi.org/10.1007/s00705-020-04834-w

[39] Al-Baroodi S, Al-Attar M. Isolation and identification of Circovirus in pigeon. Iraqi journal of Veterinary Sciences. 2020. DOI: https://doi.org/10.33899/IJVS.2020.126706.1364

[40] Sahindokuyucu I, Yazici Z, Barry G. A retrospective molecular investigation of selected pigeon viruses between 2018–2021 in Turkey. bioRxiv. 2022. DOI: https://doi.org/10.1371/journal.pone.0268052

[41] Santhanalakshmi P, Priya PM, Mani B, Ambily R, Pramod S, Anoopraj R. Standardisation of a multiplex PCR for detection of circovirus and adenovirus in pigeons. Journal of Veterinary and Animal Sciences. 2025. DOI: https://doi.org/10.51966/jvas.2025.56.4.692-697

[42] Meßmer C, Rubbenstroth D, Mohr L, Peus E, Schreiber T, Rautenschlein S. Pigeon Rotavirus A as the cause of systemic infection in juvenile pigeons (young pigeon disease).. Tierarztliche Praxis. Ausgabe K, Kleintiere/Heimtiere. 2022. DOI: https://doi.org/10.1055/a-1909-2235

[43] Tsai C, Hu S, Santos HM, Catulin GEM, Tayo L, Chuang K. Probiotic supplementation containing Bacillus velezensis enhances expression of immune regulatory genes against pigeon circovirus in pigeons (Columba livia). Journal of Applied Microbiology. 2020. DOI: https://doi.org/10.1111/jam.14893

[44] Wan C, Huang Y, Cheng L, Fu G, Shi S, Chen H, et al.. The development of a rapid SYBR Green I-based quantitative PCR for detection of Duck circovirus. Virology Journal. 2011. DOI: https://doi.org/10.1186/1743-422X-8-465